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ABSTRACT 
Antibiotic resistant bacteria are a worldwide epidemic threatening human survival. 
Antimicrobial susceptibility tests (ASTs) are important for confirming susceptibility to 
empirical antibiotics and detecting resistance in bacterial isolates. Current ASTs are based 
on bacterial culturing, which take 2-14 days to complete depending on the microbial 
growth rate. Considering the high mortality and morbidity rates for most acute infections, 
such long time frames are clinically impractical and pose a huge risk to a patient's life. A 
faster AST will reduce morbidity and mortality rates, as well as help healthcare providers, 
administer narrow spectrum antibiotics at the earliest possible treatment stage.  
In this dissertation, I developed a nonculture-based AST using an imaging and cell 
tracking technology. I track individual Escherichia coli O157:H7 (E. coli O157:H7) 
Uropathogenic Escherichia Coli (UPEC) cells, widely implicated in food-poisoning 
outbreaks and urinary tract infections respectively. Cells tethered to a surface are tracked 
on the nanometer scale, and phenotypic motion is correlated with bacterial metabolism. 
Antibiotic action significantly slows down motion of tethered bacterial cells, which is used 
to perform antibiotic susceptibility testing. Using this technology, the clinical minimum 
bactericidal concentration of an antibiotic against UPEC pathogens was calculated within 
2 hours directly in urine samples as compared to 3 days using current gold standard tools.  
Such technologies can make a tremendous impact to improve the efficacy and 
efficiency of infectious disease treatment. This has the potential to reduce the antibiotic 
mis-prescription steeply, which can drastically decrease the annual 2M+ hospitalizations 
and 23,000+ deaths caused due to antibiotic resistance bacteria along with saving billions 
of dollars to payers, patients, and hospitals. 
 
 
 
ii 
 
 
 
 
 
 
 
To my beloved 
Grandparents..Nanu, Dadi and Nanima  
For the stories which piqued my curiosity and taught me faith 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGMENTS 
I would hereby like to thank a few special people for the lifelong memories I made 
at Arizona State University. Foremost, I would like to thank my thesis advisor, Prof. 
Nongjian Tao for always having an open door to chat about research and his valuable 
lifetime experiences. I would also like to express my gratitude for the faith he kept in me 
while letting me explore my research in a multi-dimensional way. I owe my confidence 
and my passion to him. 
I would also like to acknowledge Prof. Shaopeng Wang and Prof. Shelley Haydel, 
both of whom have played a very active role in my research. Words can’t express how much 
I have cherished discussions with them, especially being healthily challenged and 
encouraged in all my endeavors. I would also like to thank my committee members, Prof. 
Kaushal Rege and Prof. Karmella Haynes, for their familiar support and valuable inputs 
over many in-person discussions. I owe my steep learning curve to them. 
I would also like to acknowledge a few special people, who have helped me develop 
in areas beyond academics. Dr. Thomas Grys, Robert Green, Dr. Vinay Nagaraj, Arjun Sen, 
Kenneth Mulligan, Holly Singh, and Brent Sebold have supported me in different ways 
during my stay along with sharing valuable advice. I owe my motivation to them. 
I would also like to acknowledge my friends and lab colleagues Yunze, Rafael, Hui, 
Wenwen, Yan Wang, Manni, Ali, Francis, Ashley, Wei, Xiaonan, Anasuya, Krupa and 
Jason, Ryan, Michelle in Haydel Lab. I thank them for valuable inputs and a good time. 
Lastly, I would like to thank my family, starting with my grandparents, my parents 
(Mr CM Syal & Indu Syal), my uncle/aunt (Dr Umesh and Sanju Jairath), for their 
upbringing. A shout out to my siblings (Shivani & Sheenam) and my wife Vijeyta, for their 
never ending love and pampering. A thank you to my brother-in-laws (Arnab & Munish), 
Apar, Rene, Dr. Arnab Mukherjee, Prads, Raghu and Pankaj for innumerable discussions 
iv 
 
which pushed me to think-out-of-box and for the perpetual guest bedroom for me.  I owe 
my inspiration to my family and friends.
v 
 
 TABLE OF CONTENTS  
Page 
LIST OF TABLES .................................................................................................................ix 
LIST OF FIGURES................................................................................................................ x 
SIGNIFICANCE AND OBJECTIVE ..................................................................................... 1 
CURRENT AND EMERGING TECHNIQUES FOR ANTIBIOTIC SUSCEPTIBILITY 
TESTS ............................................................................................................................. 4 
Introduction .................................................................................................................... 5 
Current Technologies .................................................................................................... 8 
Agar Dilution, Disk Diffusion and Antimicrobial Gradient Assays .......................8 
Broth Dilution Assay ................................................................................................11 
Emerging Technologies ................................................................................................ 12 
Imaging-based AST ................................................................................................. 13 
Non-imaging AST .................................................................................................... 16 
Biochemical AST ..................................................................................................... 17 
Future Technologies ..................................................................................................... 18 
Microcantilevers ...................................................................................................... 19 
Flow Cytometry ...................................................................................................... 20 
Isothermal Micro Calorimetry............................................................................... 20 
PLASMONIC IMAGING OF PROTEIN INTERACTIONS WITH SINGLE BACTERIAL 
CELLS ........................................................................................................................... 25 
Introduction ................................................................................................................. 26 
Materials and Methods ............................................................................................... 28 
Materials ................................................................................................................. 28 
Bacteria Purification .............................................................................................. 28 
Surface Functionalization ...................................................................................... 28 
vi 
 
Page                                                                                                                                  
Plasmonic Imaging and Flow Setup...................................................................... 29 
Bacteria Immobilization ........................................................................................ 30 
Immunofluorescence Microscopy ......................................................................... 30 
Image Collection and Processing .......................................................................... 30 
Data Analyses from Images ................................................................................... 30 
Results and Discussion ............................................................................................... 32 
Imaging Single Bacterial Cells by Plasmonic Imaging .........................................32 
Binding Kinetics of Antibody to Single Cells .........................................................34 
Validating Binding Kinetics by Control Experiments .......................................... 38 
Quantifying Bacterial Surface Heterogeneity ........................................................ 41 
Conclusion ................................................................................................................... 45 
ANTIMICROBIAL SUSCEPTIBILITY TEST WITH PLASMONIC IMAGING AND 
TRACKING OF SINGLE BACTERIAL MOTIONS ON NANOMETER SCALE....... 46 
Introduction ..................................................................................................................47 
Materials and Methods ............................................................................................... 48 
Materials ................................................................................................................. 48 
Preparation and Growth of Bacteria ..................................................................... 49 
Surface Functionalization ...................................................................................... 49 
Plasmonic Imaging and Flow Setup...................................................................... 50 
Bacterial Immobilization ........................................................................................ 51 
Image Collection and Processing ........................................................................... 51 
Sample Addition ...................................................................................................... 51 
Data Analyses from Images .................................................................................... 52 
Bacterium – Plasmon Surface Z-Distance Tracking and Z-Movement 
Calculation .............................................................................................................. 52 
vii 
 
               Page 
Results and Discussion ................................................................................................53 
Quantification of Z-Direction Motion .................................................................... 54 
Correlation Between Nano-motion and Bacterial Metabolism ............................ 56 
Changes in Nano-motion on Antibiotic Action ..................................................... 59 
Power Spectral Analysis of Nano-motion ..............................................................63 
Statistics on a Bacterial Population ...................................................................... 66 
Testing Universality of Nano-motion AST ............................................................ 67 
Conclusions .................................................................................................................. 69 
RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING OF UROPATHOGENIC E. COLI IN 
URINE SAMPLES BY TRACKING SUB-MICRON SCALE MOTION OF SINGLE 
BACTERIAL CELLS .................................................................................................... 70 
Introduction .................................................................................................................. 71 
Materials and Methods ................................................................................................72 
Materials .................................................................................................................. 72 
Preparation and Growth of Bacteria ...................................................................... 73 
Surface Functionalization ....................................................................................... 74 
Imaging and Flow Setups ....................................................................................... 74 
Bacterial Immobilization ........................................................................................ 75 
Image Collection and Processing ........................................................................... 75 
Data Analyses from Images .................................................................................... 76 
Image Segmentation and Cell Tracking Algorithm............................................... 76 
Broth Micro-Dilution Assay ................................................................................... 78 
Results and Discussion ................................................................................................79 
Quantification of the Bacterial Motion .................................................................. 81 
Effect of Antibiotic on the Sub-µm Motion .......................................................... 84 
viii 
 
               Page 
Population Level Bacteria Motion Changes on Antibiotic Action....................... 86 
Application to UPEC with Multiple Antibiotic Doses .......................................... 86 
Control Well ............................................................................................................. 87 
Bacteria Motion Responses to Clinically Relevant Antibiotic Doses .................. 96 
Single Cells Analysis and Cell to Cell Variations in Motion Responses to 
Antibiotics ............................................................................................................... 96 
Dose-curve and Defining MBC for Sub-µm Motion ............................................. 97 
Urine Samples ........................................................................................................ 98 
Conclusion ..................................................................................................................102 
CONCLUSION AND FUTURE WORK ............................................................................ 105 
Conclusions ................................................................................................................. 105 
Future Work............................................................................................................... 106 
REFERENCES .................................................................................................................. 110 
APPENDIX  
A COPYRIGHT PERMISSIONS CHAPTER 2 .......................................................... 122 
B COPYRIGHT PERMISSIONS CHAPTER 3 .......................................................... 125  
C COPYRIGHT PERMISSIONS CHAPTER 4 .......................................................... 127 
  
ix 
 
LIST OF TABLES 
Table               Page 
1-1. Summary of AST Technologies .................................................................................... 21 
3-1. Kinetics of Individual Microbial cells........................................................................ 38 
3-2. Correlation of Kinetics Parameters with Physical Attributes and Plasmonic 
Imaging Parameters ............................................................................................................ 43 
5-1. MBC of the Antibiotic at Different Concentrations of UPEC cells Spiked into 
Urine ..................................................................................................................................... 101 
 
  
 x 
 
LIST OF FIGURES 
Figure               Page 
2-1.  Evolution of Agar Dilution Methods ............................................................................. 10 
2-2. Rapid AST Using an Emerging Imaging Based Tool .................................................... 15 
3-1. Imaging Single Cells using Plasmonic Imaging Setup ................................................. 33 
3-2. Imaging Binding Kinetics using Plasmonic Imaging .................................................. 36 
3-3. Sensorgrams of Single Bacterial Cells Obtained by Plotting the Image Intensity Vs. 
Time ......................................................................................................................................... 37 
3-4. Using Fluorescent Imaging to Validate Binding Kinetics ........................................... 39 
3-5. Binding Kinetics of Negative Control ........................................................................... 40 
3-6. Distribution of Binding Constants................................................................................ 42 
3-7 Distribution of the Plasmonic Image Intensity Measured at the End of Association 
Phase for Various Bacterial Cells.......................................................................................... 43 
Table ....................................................................................................................................... 43 
4-1. Setup of Plasmonic Imaging and Tracking ....................................................................53 
4-2. Quantifying Z-direction Nano-motion of Bacterial Cells using Plasmonic Images .. 56 
4-3.  Z-movement in 1X PBS and LB medium..................................................................... 58 
4-4. Z-movement of a Bacterial Cell in Different Mediums ............................................... 60 
 ................................................................................................................................................. 61 
4-5 Observing Cell Death by Transmitted Images ............................................................... 61 
4-6. Z-movement in 1x PBS and Different Concentrations of Antibiotic .......................... 62 
4-7 Power Spectral Analysis and Z-movement Analysis of Different Bacterial Cells ....... 65 
4-8. Statistical Analysis of Amplitude Analysis Before and After Antibiotic .................... 66 
4-9. Z-movement Changes in Different Conditions ............................................................ 68 
5-1. Image Processing of Bacterial Cells to Quantitate X and Y Displacement. ................ 78 
  
xi 
 
Figure                                                                                                                                             Page 
5-2. Schematic of the Experimental Setup to Image and Track Bacterial Cell Sub-m 
Motions .................................................................................................................................. 80 
5-3. Bacterial Cells Tethered on a Surface with Sub-µm Motion ....................................... 82 
5-4. X and Y Displacement of a Bacterial Cell Compared to a Fixed Spot ........................ 83 
5-5. Sub-µm Motion Before and After Adding Antibiotic for Single Cells as Well as a 
Population .............................................................................................................................. 85 
5-6. D
AVG
 of a population of cells in different wells at various time points. ...................... 88 
5-7. Number of UPEC Cells in Different Wells over Time. ................................................. 89 
5-8. Changes in Sub-µm Motion of a UPEC Cell Replicating on the Surface.................... 90 
5-9. Changes in Sub-µm Motion of a UPEC Cell Replicating on the Surface ..................... 91 
5-10. Decrease in Sub-µm Motion of a UPEC Cell on the Surface in 0.25 µg/ml of 
Antibiotic................................................................................................................................ 92 
5-11. Increase in Sub-µm Motion of a UPEC cell on the Surface in a 0.25 µg/ml of 
Antibiotic................................................................................................................................ 93 
5-12. Decrease in Sub-µm Motion of a UPEC Cell on the Surface in a 2 µg/ml of 
Antibiotic................................................................................................................................ 94 
5-13. Decrease in Sub-µm Motion of a UPEC Cell on the Surface in a 2 µg/ml of 
Antibiotic................................................................................................................................ 95 
5-14. Comparison with Reference Techniques .................................................................... 98 
5-15.  D
AVG
 of a Population of Bacterial Cells Spiked in Urine to a Concentration of 5x10
6
 
cfu/ml. .................................................................................................................................. 100 
 
 
  1 
 
SIGNIFICANCE AND OBJECTIVE 
Discovery of antibiotics in the late 1920s led to a new era in human healthcare.1,2 
Antibiotics have since then been potent weapons against bacterial infections greatly 
improving human health outcomes.2 Antibiotics are currently widely used to keep poultry 
healthy, post invasive surgeries to prevent bacterial infections and in everyday life to treat 
common infections.3 However, over the last century their misuse and over prescription 
has led to the rapid evolution of resistance in bacteria.4 Further, lack of a foreseeable 
pipeline of future antibiotics due to lack of antibiotic research from 1970-1990s has 
compounded the problem.5 While multiple bacterial species continue to evolve rapidly in 
real-time, the world is running out of available antibiotics to treat serious infections.2,5  
This crisis is especially severe in developing countries in Asia such as India, China and 
under-developed countries in Africa, which are severely infected by bacterial diseases and 
also lack regulation to curtail misuse in healthcare as well as agriculture.3 In the next 10 
years there is a possibility of a post antibiotic era, in which house-hold minor infections 
can have a detrimental effect of patient morbidity, without available antibiotics for 
treatment.6 It’s imperative that to stop this crisis newer tools are developed which study 
these resistant bacterial cells, help the industry to make a better antibiotic pipeline and 
diagnose the resistant infections clinically at the earliest to enable accurate antibiotic use. 
Antibiotics antibiotic susceptibility tests (ASTs) are used to clinically diagnose 
resistant bacteria and prescribe accurate.7,8 The instruments performing AST are based on 
culture based technologies which have a slow turnaround time spanning 2-3 days.9 This 
slow turnaround time is clinically unacceptable and poses a huge risk to patient’s life.10 I 
discuss the detailed impact of this slow turnaround time in Chapter 2 along with an in-
depth discussion on current clinical AST devices. Further, number of emerging 
technologies at various stages of commercial development that are attempting to fulfill 
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unmet clinical needs is also discussed in Chapter 2. While these upcoming technologies 
have decreased the turnaround time of results to 6-14 hours, they need further work due 
to their dependence on culture based approaches and complex labor intensive steps 
(Chapter 2). Future technologies using a variety of culture-independent methodologies are 
geared towards providing a rapid AST results within 1-2 hours making it feasible to 
diagnose resistant bacteria at disease onset (Chapter 2). However, the lack of clinical 
application of future technologies directly to clinical samples makes their long term 
adaptation challenging.8 This thesis attempts to meet the unmet clinical need by 
developing technologies that can perform rapid AST within 2 hours on clinical samples. 
Bacterial cell-surfaces act as the first line of defense against antibiotics and play a 
crucial role in a cell’s interaction with the outside world.11–15 Further cell-to-cell surface 
diversity is critical to understand bacterial pathogenesis and resistant mechanisms.16,17  
Tools to study bacterial cell-surfaces interactions with external ligands rely mostly on 
measuring bulk bacteria, which are insufficient to study evolutionary diversity.18–20 While 
newer imaging tools have studied single cells, they are not universal and lack quantifiable 
kinetics with external ligands.12,13,21,22 In Chapter 3, I developed a plasmonic imaging tool 
(Chapter 3) to quantify the kinetic interactions of single E. coli O157:H7 with an antibody 
specific to its surface antigen.23 E. coli O157:H7 is a highly virulent pathogen implicated in 
food borne outbreaks across the world.24 I found out that the distribution of kinetic 
constants is spread over several orders of magnitude which reflects cell-to-cell 
heterogeneity in bacterial surfaces within a population. This validated the use of the 
plasmonic technique to study evolutionary diversity while developing new antimicrobials 
and humanized antibodies as future therapeutic drugs against bacterial surfaces.21,25  
I also found out that kinetic interactions are “noisy” due to small-micromotion 
present in surface tethered cells.23 This led us to hypothesize possible correlation between 
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small-micro-motion and bacterial metabolism. Traditionally, bacterial metabolism has 
been measured using culture-dependent approaches which results in long turnaround 
times for AST. In Chapter 4, using plasmonic imaging and tracking I found out that alive 
tethered bacterial cells move on the surface with nano-meter amplitude (nano-motion).26 
Further, I showed that nano-motion is correlated with bacterial metabolism and decreases 
on antibiotic action in real-time, enabling rapid susceptibility testing in a culture-free way. 
While plasmonic imaging technique is a considerable advance in the field, its long term 
clinical adaptation might be limited due to its complex optical setup.8  
For easier clinical adaptation I set out to enable simple brightfield microscopes, 
present commonly in clinical labs across the healthcare world, to perform rapid AST using 
motion tracking. I used UPEC strain, implicated in 75% urinary tract infections in the 
world.27 In chapter 5 I demonstrated that via an optimal combination of surface chemistry, 
hardware changes and automated image processing algorithms, I can perform 
susceptibility testing by quantitating the sub-µm motion of bacterial cells (Chapter 5). The 
sub-µm motion is dependent on surface tethering, bacterial replication cycle and nutrient 
conditions. I measured the clinical metric of minimum bactericidal concentration of an 
antibiotic against UPEC strains directly in urine samples within 2 hours enabling point-
of-care use (Chapter 5). This has the potential to enable clinical microbiology lab to 
perform rapid AST on clinical urine samples. 
In this thesis I developed a technique in Chapter 3 to aid future antibiotic research 
and study bacterial surface heterogeneity. In Chapter 4 and 5, I developed two imaging 
tools to enable rapid, point-of-care AST in the healthcare system. To achieve the promised 
impact, I have discussed in Chapter 6 major conclusions from study, multiple future 
strategies and potential pitfalls to address. Overall, this thesis aims to deliver immediate 
patient relief in the short term while strategizing to save antibiotics in the long run.  
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CURRENT AND EMERGING TECHNIQUES FOR ANTIBIOTIC SUSCEPTIBILITY 
TESTS 
Infectious diseases caused by bacterial pathogens are a worldwide burden. Serious 
bacterial infection-related complications, such as sepsis, affect over a million people every 
year with mortality rates ranging from 30% to 50%. Crucial clinical microbiology 
laboratory responsibilities associated with patient management and treatment include 
isolating and identifying the causative bacterium and performing antibiotic susceptibility 
tests (ASTs), which are labor-intensive, complex, imprecise, and slow (taking days, 
depending on the growth rate of the pathogen). Considering the life-threatening condition 
of a septic patient and the increasing prevalence of antibiotic-resistant bacteria in 
hospitals, rapid and automated diagnostic tools are needed. This review summarizes the 
existing commercial AST methods and discusses some of the promising emerging AST 
tools that will empower humans to win the evolutionary war between microbial genes and 
human wits. 
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Introduction 
Antibiotic-resistant bacterial pathogens are a global health epidemic, spreading at 
a rapid rate. In the US alone, these pathogens costs billions of dollars in healthcare, with 
2 million hospitalizations and 23,000 deaths annually.28 This epidemic is accelerated by 
widespread misuse of antibiotics in clinics and agriculture over the last few decades, 
allowing bacteria to evolve and develop means of resistance.2,3 Resistant bacteria are 
widely found in the community and can also be acquired via nosocomial infections, post-
surgery complications, and contaminated food.2,29 Resistant bacterial infections can also 
cause sepsis, which has mortality rates ranging from 30% to 50%.30 Considering the life-
threatening condition of a septic patient, a key clinical task is prescribing the patient with 
effective antibiotics, which requires rapid diagnosis of the resistant infections and 
antibiotic susceptibility testing (AST).10 
AST is widely used clinically to determine antibiotic resistance profiles of bacterial 
isolates, to guide antibiotic treatment decisions, and predict therapeutic outcome.30,31 
Currently, AST is usually performed in a clinical microbiology lab, which necessitates 
transportation of the patient samples from the healthcare provider to the lab. 
Susceptibility testing requires a pure culture of the offending pathogen, a process which 
may take several days.  This delay prolongs the time to diagnosis of resistant bacteria and 
decisions for appropriate and effective antibiotic therapy. Delays in timely administration 
of appropriate therapeutics lead to increased patient mortality, poor clinical outcomes,30 
and use of broad-spectrum antibiotics, the latter of which promotes antibiotic resistance. 
To survive this evolutionary war against bacteria, humanity must pursue technologies that 
can rapidly perform AST to enable personalized therapies (narrow-spectrum antibiotic 
administration) at the earliest possible treatment stage.  
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After receipt of the patient sample (collected on day 0), the clinical microbiologist 
must isolate the potential pathogen by streaking the sample on selective culture media and 
incubating the inoculated media overnight (or longer) to enable growth.  From a primary 
growth plate (day 1), isolated colonies must be obtained by subculture. Once isolated 
colonies from the pathogenic organism are available (day 2), the bacterial inoculum is 
prepared and standardized (day 2) prior to performing AST via disk diffusion31or broth 
dilution32 methods (detailed later).  
The minimum inhibitory concentration (MIC) is defined as the lowest 
concentration of antibiotic required to prevent bacteria growth and is used to determine 
if the infected pathogen is susceptible or resistant to an antibiotic.4,31,32 It is important to 
note that the MIC does not necessarily imply bacterial death, but rather lack of growth.  
Thus, the MIC differs from the Minimum Bactericidal Concentration (MBC), a useful value 
which is seldom determined in a clinical laboratory because of the additional effort 
required.  A breakpoint is defined as the concentration of an antibiotic that enables 
interpretation of AST to define isolates as susceptible, intermediate, or resistant.32,33 If the 
determined MIC is less than or equal to the breakpoint, then the bacterial isolate is 
considered susceptible to the antibiotic. Clinical breakpoints for different antibiotics and 
bacteria are reviewed and updated annually by national organizations, such as the Clinical 
Laboratory Standards Institute (CLSI) in the USA and the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST).32 In addition to characterizing bacterial 
isolates collected from individual patients, MIC is used in epidemiological monitoring of 
the evolution of antibiotic-resistant bacteria. Increasing MIC values for an antibiotic over 
a period of time may indicate acquired antibiotic resistance for a given bacterial species.32 
MIC values serve as an important parameter to determine phenotypic resistance in 
bacterial cells, to monitor the global resistance surveillance, and to determine the 
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effectiveness of new antibiotics. MIC values obtained by the current AST techniques also 
serve as a gold standard to evaluate new AST methods.  Another concept that is becoming 
a useful analytic modality is the Epidemiological Cutoff Value for resistance (ECOFFs).34 
This relates to the MIC values of a population of isolates of a particular organism against 
a particular drug.  It can be helpful to determine intrinsic resistance that is present in some 
strains of a bacterial species. 
The current culture-based AST tools rely on time-consuming culturing techniques, 
followed by disk diffusion31 and broth dilution susceptibility testing32, resulting in several 
days before MIC values are determined and reported. Paradigm-shifting AST technologies 
must overcome the current bottleneck associated with the slow culturing steps. Ideally, 
they would be directly applicable on clinical samples without the need for selection and/or 
enrichment on day1, and, preferably, be able to deliver results at the point of care (i.e., at 
the patient’s bedside). In addition to low cost and ease of operation requirements, 
additional features, such as identification of bacterial strains before AST and the ability to 
perform AST of polymicrobial infections, will also help improve patient outcomes and 
reduce the selection of additional resistant organisms. 
In the present mini-review, I summarize the current technologies, discuss the 
emerging technologies, and provide scientific opinions on future AST technologies. Given 
the vast number of publications in this area, I mainly focus on phenotypic AST methods. 
Even with this focus, I will unintentionally and inevitably exclude many exciting emerging 
technologies in the scientific literature due to limited page and scope. Fortunately, several 
reviews4,31,35,36 on related topics have been published, thus enabling readers to identify 
topics that are inadvertently not included here.  
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Current Technologies 
In 1928, Alexander Fleming discovered a mold that prevented the growth of 
staphylococci on an agar plate (Figure 2-1a). The mold produced an active substance, 
penicillin, which become the first antibiotic and usher in the antibiotic era, a critically 
important milestone in modern medicine.1 Antibiotics are commonly used to treat 
bacterial infections, to reduce the possibility of infections (e.g., during invasive surgeries) 
in hospitals, and to promote growth in food animals. The widespread use of antibiotics has 
accelerated the pace at which bacteria become resistant to antibiotics. While antibiotic-
resistant bacteria are rapidly evolving, diagnostic technologies that can characterize the 
infection, guide treatment, minimize unnecessary use of antibiotics, and customize 
therapeutic strategies for specific patients have been slow. The mainstream technologies 
still rely on measuring bacterial growth in presence of antibiotics over a few days using 
methods such as agar dilution assays (E-test and disk diffusion), broth dilution assays, and 
automated systems from various manufacturers. These technologies rely on detecting 
bacterial growth, which is not conceptually different from how Fleming first discovered 
penicillin. 
Agar Dilution, Disk Diffusion and Antimicrobial Gradient Assays 
In the agar dilution assay, bacteria are inoculated into an agar medium containing 
different antibiotic concentrations. While agar dilution testing offers reproducible results, 
agar dilution plates are laborious to prepare and have short shelf lives. In many clinical 
microbiology laboratories, an agar disk diffusion is routinely used for testing common, 
rapidly growing bacterial pathogens.31 The disk diffusion assay involves inoculating the 
bacteria, enriched from clinical samples by overnight growth on selective media, onto a 
Mueller-Hinton agar plate, followed by placing commercially-prepared filter paper disks 
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impregnated with predetermined concentrations of an antibiotic onto the surface of the 
agar medium.35 The agar plate containing the bacteria inoculum and antibiotics disks are 
further incubated at 35-37°C in ambient air or 5% CO2 for 16-24 hours, depending on the 
suspected bacterium. During this incubation, the antibiotics diffuse into the agar with 
antibiotic concentration decreasing with increasing distance from the disk. Antibiotic 
susceptibility is determined by measuring the diameter of the zones of bacterial inhibition 
around the antibiotic disks and comparing the diameter with disk diffusion interpretive 
criteria updated annually by CLSI.35,37 While the disk diffusion test (Figure 2-1b) is 
technically easy, inexpensive, and flexible, it provides only categorical results (e.g., 
susceptible, intermediate, resistant). Since quantitative MIC results relaying the degree of 
susceptibility may be necessary in some cases, the gradient diffusion method offers similar 
flexibility and simplicity to disk diffusion and determines quantitative MICs. In the E-test, 
a common commercially-available gradient test, the assays are performed similarly to the 
disk diffusion approach except that a thin plastic strip with a continuous exponential 
gradient of antibiotic is used to generate diffusion of the antimicrobial agent into the agar-
based medium. After overnight incubation allows bacterial growth and antibiotic diffusion, 
an inhibition ellipse is visible (Figure 2-1c). The quantitative MIC corresponds to the point 
on the strip whereby the antimicrobial concentration is no longer inhibiting bacterial 
growth, thus revealing the inhibitory concentration. The disk diffusion and E-test methods 
are commonly used in clinical microbiology labs.  
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a b 
c 
Figure  
2-1.  Evolution of Agar Dilution Methods  
a) Determining antibiotic susceptibility from the discovery of antibiotics currently 
used disk diffusion (b) and E-test (c) assays. a) Photograph showing lack of 
staphylococcal colonies in the vicinity of the Penicillium mold adapted from Alexander 
Fleming’s original research paper on the discovery of penicillin. b) E-Test uses 
gradient antibiotic concentrations to determine MIC of antibiotics. c) Disk diffusion 
assays involve placing multiple antibiotic-impregnated disks onto an agar surface 
inoculated with bacteria and measuring the diameter of zones of inhibition to 
qualitatively determine antibiotic susceptibility. Figure 2-1a Adapted from – Alexander 
Fleming. On the Antibacterial Action of Cultures of a Penicillum, with Special Reference to their use in 
the isolation of B. Influenze. Br J ExpPathol. 1929 Jun; 10(3): 226–236Disk diffusion assay image 
produced by John Popovich, Haydel Lab, ASU. E-test image produced by Rachael Liesman 
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Broth Dilution Assay 
An MIC test can also be performed using broth macrodilution, whereby broth 
volumes for testing each antibiotic concentration are at least 1 mL. Following incubation 
for 20-24 h, the MIC is the lowest concentration of antibiotic that completely inhibits 
bacterial growth and therefore lacks visible turbidity.32 Due to the laborious nature of the 
broth macrodilution approach, the assay has been miniaturized and standardized by use 
of small, plastic, disposable microdilution trays which contain 96 wells to allow minimal 
volume (e.g.: 0.1 mL) and pre-determined antibiotic concentrations.31 Many 
commercially-available systems use automatic inoculating devices, but microwells may 
also be inoculated with multichannel pipettes. Broth microdilution results may be 
determined visually or through automated instruments.  
Automation of the broth microdilution assay instruments provides more precise, 
reliable, and quantitative AST. There are four commercially-available automated or semi- 
automated instruments MicroScan WalkAway, Vitek-2, BD Phoenix automated system, 
and Sensititre.31,33  Each of these instruments consists of the following: 1) A single-use AST 
cassette, which can be a microdilution tray/test panel/card containing different antibiotics 
at different concentrations; 2) an AST instrument, which reads multiple cassettes over a 
period of time (usually overnight) to give AST results. These automated AST instruments 
require bacterial isolates obtained through routine culture from the patient samples. 
Microscan Walkaway AST cassette, based on standard 96-well microdilution trays, 
is capable of handling 40-96 trays with automated sample-handling robotics, where the 
antibiotic susceptibility test uses a photometer to detect bacterial turbidity in the trays 
over 4.5-18 hours.31,32,38 The Vitek-1/Vitek-2 AST instruments developed by bioMérieux, 
use a smaller AST cassette, called an AST card, in the 45-64 well plate format. Each Vitek-
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2 AST instrument is capable of handling 30-240 AST cards and detects turbidity with 
bacterial growth over 4-10 hours to reveal AST results. The BD Phoenix is an automated 
microbiology system that consists of a large AST instrument capable of reading turbidity 
and colorimetric changes of up to 99 AST cassettes (called panels). The BD system requires 
an average of 6-16 hours, starting from incubating pure bacterial cultures, to obtain MIC 
for the bacteria. The Sensititre system by Thermo Scientific uses the standard 96-well 
microdilution panels (AST cassettes), which are inoculated by the Sensititre 
Autoinoculator, and is capable of handling 64 panels. Bacterial growth in each panel is 
detected from the fluorescent intensity monitored over 18-24 hours post incubation.  
Automated AST instruments, representing current state of the art technologies, are 
extensively used in clinical microbiology labs in the US. Compared to manual methods, 
these instruments provide a streamlined workflow and quantitative results, thus 
simplifying MIC determinations for pathogenic bacteria isolated from clinical samples.39 
However, these automated instruments still require the use of isolated bacteria grown in 
pure culture, and the susceptibility tests are based on measuring bacterial growth and 
turbidity changes. As a result, these automated technologies remain inherently slow and 
are severely limited by the low sensitivity of the current detection methods. Furthermore, 
they are limited in the number of antibiotics and concentrations tested and lack the 
capability of analyzing polymicrobial samples or heterogeneous response of bacterial 
populations to the antibiotics.  
Emerging Technologies 
Newer AST techniques, which are currently and actively being pursued by 
commercial entities for clinical translation, are considered as emerging technologies for 
the purpose of this review. With the increasing clinical demand for rapid AST, various new 
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AST techniques based on optical imaging,40–42 micro-channel resonators43–45 and other 
biosensors46,47 have been pursued. For example, optical detection of bacterial growth via 
the cell lengths and numbers,40,42,48 forward light scattering,47 and measuring vibrational 
amplitude changes of magnetic beads,46,49 have been proposed. Micro-channel resonators 
have also been used to detect nanoscale fluctuations associated with bacteria growth.43 
Quantitating molecular or biochemical markers, such as 16SrRNA,50 ATP,51 and 
luciferase,52 in bacterial cells are also being used for rapid AST. These approaches can 
significantly improve the current commercial AST technologies, but they still rely on 
culturing, which is not universally applicable for anaerobes, slow-growing bacteria, and 
non-cultivable microorganisms. Additionally, most of these emerging technologies still 
require substantial sample preparation and pre-treatment steps, such as bacterial 
enrichment from patient samples, and cell lysis to extract biochemical markers. 
Imaging-based AST 
Multiplexed automated digital microscopy (MADM)41,53 is an automated 
microscope being developed to provide rapid identification and AST of clinical samples. 
MADM separates bacterial cells from other substances in the clinical samples(e.g., blood 
or urine) using gel filters and attaches purified bacterial cells to the surface sensing surface 
using electro-kinetic loading.53 After surface attachment, fluorescent in-situ hybridized 
(FISH) probes are used to identify bacterial cells within an hour, followed by AST.53 To 
perform AST, MADM measures bacterial growth every 10 minutes as clonal aggregates 
multiply in Mueller-Hinton media. Since resistant cells will grow in Mueller-Hinton media 
with antibiotics and sensitive cells will be inhibited or killed, expansion and measurement 
of clonal masses over time (compared to growth controls) are used to generate growth 
curves and determine susceptibility. MADM also uses cell morpho-kinetic image analysis 
for differentiating bacterial species in polymicrobial infections, thus expanding clinical 
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capability and reducing of the cost of multiple assays. While the MADM imaging approach 
for measuring the bacteria growth rate is faster than traditional approaches and represents 
a significant step forward from the current commercial tools, its universality to all 
antibiotics remains to be addressed.40 
Another imaging tool capable of rapid AST is single-cell morphological analysis 
(SCMA).40,54 SCMA (Figure 2-2) uses bright-field microscopy to determine antibiotic-
induced morphological changes in single bacterial cells and enable rapid AST. The 
captured images are processed using an automated image-processing algorithm to 
quantify the area and number of growing bacterial cells. The classification algorithm 
processes several morphological characteristics to produce antimicrobial susceptibility 
data. Another optical imaging technique is oCelloScope,55,56 which is based on imaging 
growth of a population of bacterial cells in a fluid sample with antibiotics over a period of 
time. The recorded images are then processed using imaging algorithms to quantify 
changes in the area occupied by a growing population of cells. However, unlike other high 
resolution imaging methods, oCelloScope does not capture the growth of individual cells, 
but a population of cells in liquid fluids and thus eliminates the need to attach bacterial 
cells to an inert surface. 
Coupling of imaging-based tools with microfluidics has been reported for rapid 
AST. Bacterial cells are first captured in microfluidic chambers,57 micro channels,58 or 
droplets 59,60 and then imaged to detect changes in the cell number,42,61 size,40 
morphology62 and viability59,63 in the presence of antibiotics in order to perform AST. 
Novel imaging approaches, such as measuring changes in rotational frequency of magnetic 
beads (which is proportional to cell mass) 46,49,64 and electro-kinetic loading of single 
cells,58 have been applied to AST using smartphone cameras and other imaging devices.63 
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Figure  
2-2: Rapid AST Using an Emerging Imaging Based Tool 
a) Schematic comparison of traditional AST using broth microdilution and imaging-
based AST demonstrates how tracking single cell divisions can produce rapid results 
compared to traditional optical density (OD) tools which are limited by their sensitivity 
to measure only higher bacterial concentrations. b) Setup of a 96-well plate modified 
into a microfluidic agarose chip for concurrent addition of bacteria and antibiotics 
followed by microscopic imaging. c) Schematic of steps involved in adding bacteria and 
antibiotics and imaging a localized area to observe changes. Adapted from Choi J, Yoo J, Lee 
M, Kim E-G, Lee JS, Lee S, et al. A rapid antimicrobial susceptibility test based on single-cell 
morphological analysis. Sci Transl Med 2014; 6:267ra174 Reprinted with permission from AAAS. 
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Although the imaging-based AST tools shorten the detection time from days to a 
few hours, these technologies still use replication-dependent methodologies that have a 
primary culture step (e.g. growth from a blood culture bottle or growth on a primary 
culture plate). These dependencies limit the application of imaging-based methods to 
slowly-growing pathogens, such as Mycobacterium tuberculosis. To perform AST on 
pathogens directly (i.e.: without a culture step) from clinical samples, it is necessary to 
separate bacteria from the patient sample matrix, and then measure a cellular attribute 
that is independent of replication. 
Non-imaging AST 
Non-imaging methods that measure the physical or biochemical signature of 
bacterial cells have been proposed for AST. BacterioScan detects forward laser light 
scattering (FLLS) 47,65 analyzes the angular variation in the intensity of the scattered light, 
and determines the number and size of bacterial cells suspended in a solution. FLLS can 
measure bacterial concentrations as low as 103cfu/ml, which is more sensitive than other 
optical methods and traditional automated instruments, and may enable rapid AST 
(within a few hours). The FLLS technology can perform AST directly on urine samples 
with minimal sample preparation, thus enabling point-of-care applications. 
Disadvantages of FLLS include the use of a replication-dependent approach to measure 
AST, inability to differentiate bacteria from cell sedimentation, lack of single cell 
resolution, and inability to differentiate bacterial species for polymicrobial analysis. 
LifeScale develops microchannel resonators for rapid AST, where the 
microchannel resonators are individual microcantilevers. The technology measures the 
mass of the bacterial cells upon passage through the microfluidics channels inside of the 
micro-cantilevers.45 Microchannel resonators permit quantitation of bacterial cells and 
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measure mass changes of the individual cells to assess antibiotic activity.43,45,66 The 
advantages of microchannel resonator AST are the ability to perform sensitive mass and 
morphology measurements on single bacterial cells and the promise of AST within~3 
hours. However, the applicability of the approach to clinical samples remains to be fully 
established.  
Biochemical AST 
While the AST technologies described above detect physical and morphological 
features of bacteria, tools that measure molecular and biochemical signatures, such as 
changes in 16s RNA,50,67 DNA68,69 and ATP,51 of growing bacterial cells have also been 
studied. A biosensor-based AST (b-AST) assay being developed by Genefluidics measures 
bacterial growth via quantitating 16s rRNA molecules, which are specific for each bacterial 
species.50,67 After DNA probes hybridize specifically to 16S rRNA molecules, an 
electrochemical signal permits amplification and quantitative detection. This approach 
allowed for AST as short as ~4 hours using clinical urine samples from patients 
experiencing a urinary tract infection. Smarticles technology in development by Roche 
Diagnostics52 introduces recombinant bacteriophages with DNA probes, such that a 
specific binding of DNA probes inside the bacterial cells leads to luciferase expression. 
Luciferase expression produces light, which is used to quantify the number of bacterial 
cells and perform rapid AST. Real-time PCR is another molecular approach, which 
quantifies copies of bacterial DNA and correlates this value with bacterial growth in a 
sample. This technique targets highly conserved regions of bacterial chromosomal DNA 
to ensure species specificity and has been applied to various combinations of antibiotics 
and bacterial species. Another approach detects bacterial genetic fingerprints that are 
detected upon exposure to antibiotics rather than relying on a single specific gene or DNA 
sequence in the other approaches described above.  
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While the nucleic acid-based biochemical assays, such as real-time PCR, can give 
faster results than the current techniques, it has several disadvantages such as relying on 
high bacterial concentrations to extract sufficient DNA, manual sample handling steps 
such as lysing bacterial cells to extract nucleic acids.70 These manual steps make clinical 
adaptation of these technologies difficult, where the need of the hour is rapid automated 
testing. Further the extracted DNA contains DNA from both alive/dead cells leading to a 
higher false positive rate for these techniques.71 Other disadvantages include the need of 
previously known sequences, micro-heterogeneity in the 16s RNA within a species, 72 lack 
of correlations between genotypic and phenotypic resistance,73 and inability of performing 
tests on clinical samples. 
Other biochemical signatures, such as ATP and NADH, have been studied as AST 
biomarkers with electrochemical amplification.51,74–76 These biochemical signatures are 
indicators of the metabolic activities of bacteria, thus providing critical information on 
bacterial viability. While some of these techniques are capable of providing rapid AST 
within a few hours, these techniques currently lack sensitivity to perform AST at lower 
antibiotic concentrations and dilution ranges. Further, the universal application of the 
probe molecules to multiple strains and antibiotics is also questionable. While promising, 
these emerging approaches require further studies and evaluations. 
Future Technologies 
The emerging technologies, being actively pursued by commercial entities 
discussed above, promise rapid AST within a few hours. Furthermore, some of the 
technologies can be directly applied to patient samples without any sample pretreatment. 
However, further shortening the test time and applying them to slowly growing organisms 
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will require innovative approaches. I discuss future technologies that can meet these 
requirements below. 
Microcantilevers 
Microcantilevers have been recently used to perform rapid AST,44,77,78 whereby 
bacterial cells are attached to a microcantilever and deflection of the microcantilever 
associated with the micromotions of the bacterial cells, is detected as the signature of 
bacterial metabolism. This approach has led to AST within two hours for Escherichia coli 
and Staphylococcus aureus strains for different antibiotics 44,77. The correlation between 
the micromotions and viability (metabolism) has been studied for both prokaryotic and 
eukaryotic cells 79. While sensitive, the micromotion of bacterial cells producing 
microcantilever deflections is affected by flowing liquids, and recent reports have also 
indicated inefficient transfer of antibiotics to immobilized bacterial cells under laminar 
flow conditions 45. Furthermore, the sensitive cantilever deflections are caused by bacterial 
cells attached to the tip, so the small area of the tip limits the number of bacterial cells 
which are adsorbed to the surface, potentially preventing the application of the technique 
to lower bacterial concentrations present in clinical samples 45. It is unclear how this 
approach can be applied directly to complex matrix of clinical samples and polymicrobial 
systems. Given that eukaryotic cells can also cause cantilever fluctuations,79 sample 
preparation for this technique might need extraction of bacterial cells from complex 
matrix along with a longer incubation of bacterial cells to attach the sensor surface, 
especially for low bacterial load patient samples. 
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Flow Cytometry 
Flow cytometry (FC) measures changes in morphology, cellular numbers, and 
viability via labeling to perform AST 80–82. After a dye is used to stain viable cells, individual 
cells flow  through a channel into a reader zone, where light scattering is used to measure 
morphology and excitation/emission spectra of cells is used to assess cell counts and 
viability. Multiple research studies have shown the application of this technology using 
various dyes 81,82 applied to multiple bacterial species and antibiotic combinations. 
Although flow cytometry can produce rapid AST with 2-3 hours, it is not a widely used 
technique yet. Possible disadvantages are lack of use in complex patient samples, staining 
inefficiency of dyes, presence of auto-fluorescence, inability to differentiate cellular 
damage caused by bactericidal or bacteriostatic antibiotics, and lack of clinical databases 
for validation 83. 
Isothermal Micro Calorimetry 
Isothermal micro calorimetry (IMC) is a novel technique that measures cumulative 
heat and generates heat curves of growing bacterial cells 84. Heat curves of growing 
bacteria are similar to the growth curve measured by standard turbidity detection 
instruments. Since the lower limit of detection for IMC is ~ 104cfu/ml, the approach 
enables a faster AST 84. IMC produces AST results within 3 hours using patient urine 
samples 85 and has been effective with various bacterial species, including Mycobacterium 
tuberculosis 86, E. coli, and S. aureus 84. Although this new analytical tool uses a new 
signature of bacterial metabolism to perform AST, heat curves do not correlate with 
current standard techniques and do not shorten the time to generate MIC considerably 
due to dependence on culturing tools. Other discrepancies such as delays in onset of 
detectable heat due to insufficient bacterial numbers and lack of cellular level metabolic 
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understanding of heat curves limit its current clinical use. While novel, sample 
preparation might involve purification of bacterial samples by overnight culturing to 
enable translation of this technique to complex clinical samples such as blood and sputum. 
This novel tool needs to be advanced further and studied in more to meet the expectations 
of current rapid AST.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 
1-1. Summary of AST Technologies
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AST 
Technologies 
Summary of Method 
Time of 
AST 
Direct on 
patient 
sample 
Real 
MIC 
FDA 
Approval 
Reference 
Current Technologies 
Solid Media Cultures 
1. Agar Dilution 
Assay 
Bacteria inoculated on agar plates 
with antibiotic discs of different 
concentrations 
16-24 
Hours 
No Yes/No Yes 31 
2. Disk Diffusion 
Bacteria inoculated on agar plates 
with a single antibiotic disk 
16-24 
Hours 
No Yes/No Yes 31,35 
3. E-test 
Bacteria inoculated on agar plates 
with a graded antibiotic concentration 
strips 
16-24 
Hours 
No Yes Yes 31,35 
Liquid Media Cultures 
1. Broth Dilution 
Assay 
Bacteria inoculated in liquid media 
with different antibiotics to monitor 
growth 
12-24 
Hours 
No Yes Yes 31,33 
2. Automated Instruments 
a) MicroScan 
WalkAway 
Measure bacterial growth in the 
presence of antibiotics by recording 
bacterial turbidity using a photometer 
4.5-18 
Hours 
No Yes Yes 32,38 
b) Vitek-1/Vitek-2 
Measure bacterial growth in the 
presence of antibiotics by recording 
bacterial turbidity using a photometer 
6-11 
Hours 
No Yes Yes 39,87 
c) BD Phoenix 
Record bacterial growth in the 
presence of antibiotics by recording 
bacterial turbidity and colorimetric 
changes 
9-15 
Hours 
No Yes Yes 88 
d) Sensititre 
Record bacterial growth with 
antibiotics by measuring fluorescence 
18-24 
Hours 
No Yes Yes 31 
Emerging Technologies 
Imaging Based Tools 
1. Multiplexed 
automated digital 
Image single bacteria growing into 
colonies with antibiotics and quantify 
growth rates 
3-5 
Hours 
Yes (Urine, 
Blood) 
Yes Yes 
53,89,90 
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microscopy 
(MADM) 
2. Single-cell 
morphological 
analysis (SCMA) 
Image single bacterial cell's 
morphology changes on antibiotic 
action 
3-4 
Hours 
Yes (Urine) Yes No 54,91 
3. oCelloscope 
Measure growth of bacterial cells 
using low resolution optical system 
1-4 
Hours 
Yes (Urine) Yes No 55 
Non-Imaging Based Tools 
1. BacterioScan 
FLLS 
Measures bacterial numbers and sizes 
on antibiotic action 
3-10 
Hours 
Yes (Urine) Yes No 47,65 
2. LifeScale 
Micochannel 
Resonator 
Count bacterial cells and morphology 
changes on single cells post antibiotic 
action 
> 3 
Hours 
No Yes No 66 
3. Genefluidics 
Count 16s RNA increase as a proxy to 
bacterial growth 
4 Hours Yes (Urine) Yes/No No 67,92 
4. Smarticles 
Bacteriophages which express 
luciferase on growing cells 
- - - No 52 
Future Technologies 
1. AFM Cantilever 
Measure cantilever fluctuations 
originating from bacterial motion as a 
proxy for metabolism 
< 2 
Hours 
No Yes No 44 
2. PIT 
Image and Quantify sub-nanometer 
motion of bacterial cells 
< 2 
Hours 
Yes 
Unkno
wn 
No 26 
3. Flow Cytometry Count viable bacterial cells using dyes 
2-3 
hours 
No Yes No 80 
4. IMC Heat signature of growing cells 
3-14 
Hours 
Yes Yes No 85 
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Conclusions 
Current manual and automated AST technologies are the backbone of today’s 
clinical microbiology labs. Given their ease-of-use, relatively low cost to perform AST and 
prevalence across the globe, they will be indispensable in the immediate future. In the near 
future, I anticipate that the emerging and future innovative technologies, such as MADM, 
AFM and IMC, will lead the next wave of more powerful AST tools for rapid clinical 
diagnostics. Future tools to measure bacterial metabolic activity in real-time without 
culturing will be a quantum leap forward from the existing commercial AST technologies. 
These tools will enable a one-hour AST, within the time span of an outpatient clinical visit. 
Such rapid and real-time AST tools will not only help save lives,10 but also have the 
potential to enable accurate antibiotic treatment at disease onset, potentially slowing the 
evolution of antibiotic resistance and improving antibiotic stewardship. Given the ever-
increasing spread of antibiotic resistance, we must develop innovative technologies which 
permit rapid AST within an hour, can be applied to fluids collected directly from the 
patient, and are applicable to slow-growing and non-cultivable microbes. 
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PLASMONIC IMAGING OF PROTEIN INTERACTIONS WITH SINGLE BACTERIAL 
CELLS 
Quantifying the interactions of bacteria with external ligands is fundamental to the 
understanding of pathogenesis, antibiotic resistance, immune evasion, and mechanism of 
antimicrobial action. Due to inherent cell-to-cell heterogeneity in a microbial population, 
each bacterium interacts differently with its environment. This large variability is washed 
out in bulk assays, and there is a need of techniques that can quantify interactions of 
bacteria with ligands at the single bacterium level. In this work, we present a label-free 
and real-time plasmonic imaging technique to measure the binding kinetics of ligand 
interactions with single bacteria, and perform statistical analysis of the heterogeneity. 
Using the technique, we have studied interactions of antibodies with single Escherichia 
Coli (E. coli) O157:H7 cells and demonstrated a capability of determining the binding 
kinetic constants of single live bacteria with ligands, and quantify heterogeneity in a 
microbial population. 
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Introduction 
Bacteria interact with environment through their surface constituents, such as 
lipid bilayers, peptidoglycan layers, lipopolysaccharides (LPS), pilli, flagella and outer 
membrane proteins. The surfaces of bacteria act as the first line of defense against harmful 
external stimuli, including antibiotics11 and antimicrobial peptides,12,13 and also play 
crucial roles in interacting with other surfaces, including host tissues14 and medical 
plastics,15 to help bacterial cells attach and colonize. In order to survive in a changing 
environment, bacteria replicate and evolve quickly,16,17 leading to diversity of different 
bacteria species, and variability within the same species 17,93. It is thus important to study 
and quantify the interactions of bacteria with external ligands at the single bacterium level. 
The interactions of external ligands and bacteria have been studied using ex situ 
and in situ approaches, such as fluorescence assay,21 quartz crystal microbalance (QCM)94, 
surface plasmon resonance (SPR)19,20, microcantilevers44 and atomic force microscope 
(AFM).12,15 The ex situ approaches include the study of reconstituted artificial membranes 
95,96, membrane protein embedded liposomes 97, and extracted surface constituents (e.g., 
membrane proteins 98 and sugars99 from bacteria. Given the complexity of the bacteria, in 
situ study of intact bacterial cells in their native environments are more attractive 100. 
 Traditional studies of intact bacteria cells are largely based on bulk assays and 
susceptibility testing assays, using techniques such as SPR 18–20 and disk-diffusion 31. The 
data generated with these bulk assays are averaged over many bacteria, which wash out 
important variability or heterogeneity of different bacterial cells. Various imaging 
techniques, such as fluorescence 13,21, AFM12,15 and transmission electron microscopy 
(TEM)21, and non-imaging microfluidics techniques, such as flow cytometry 101 and micro 
electrophoresis 17, have been used to study bacterial surfaces. These techniques have 
contributed to the understanding of bacteria, but each has disadvantages. For example, 
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the fluorescence method requires labeling, which limits its application to only certain 
probe molecules and cultivable strains, and gram negative bacteria with sugars cannot be 
easily labeled by engineering cells 22. In addition, the fluorescence method is an end-point 
assay, which is not suitable for quantifying the kinetics of molecular binding to bacteria. 
TEM requires extensive sample preparations and is unsuitable for live cell analysis in 
aqueous solutions. AFM can operate in aqueous solutions, but it is usually too slow to 
follow fast binding of ligands with bacteria, and the scanning AFM probe may perturb the 
binding process. In this study, we present a plasmonic imaging technique 102–104 (Figure. 
3-1a) to study and quantify the interactions of a single E. Coli O157:H7 cell with an 
antibody, and perform statistical analysis of the bacterial heterogeneity. 
 E. Coli O157:H7 is a highly virulent food borne pathogen that causes diseases, such 
as diarrhea, hemorrhagic colitis and hemolytic uremic syndrome 24. Many groups have 
tried detecting this pathogen by several culture assays as well biosensing approaches.  
Several groups have used conventional SPR to detect E. Coli O157:H7 by direct detection 
of bacterial cells binding to surface (Tawil et al., 2012; Torun et al., 2012) , indirect 
detection of surface immobilized cells using complementary probes19,20 or coupling SPR 
with other techniques.108 In this study, we focus on the binding kinetics of goat anti-E Coli 
O157:H7 IgG polyclonal antibody(Ab157)19,20 onto single E. Coli O157:H7 cells. 
Commercial humanized antibodies are increasingly used as an alternate therapy for 
immune clearance of pathogens,21,109 hence the study of antibody binding kinetics with 
single bacterial cells is important to elucidate their efficacy and potential as future drugs.  
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Materials and Methods 
Materials  
Lyophilized Bacterial pellets of E. Coli O157:H7 (ATCC43888) were purchased 
from Fisher Scientific. Affinity purified goat anti-E. coli O157:H7 IgG and anti-E. coli 
O145:H7 polyclonal antibodies were purchased from Kirkegaard and Perry Laboratory Inc. 
(Gaithersburg, MD) and suspended in 1ml PBS (1x). Secondary antibody Alexa Fluor 555 
rabbit anti-goat IgG (H+L) was purchased from Life Technologies (Carsbad, CA). (1-
Mercapto-11-undecyl) hexa(ethylene glycol) (PEG) and Carboxyl-terminated 
hexa(ethylene glycol) undecane thiol (PEG-COOH) was purchased from Nanoscience 
Instruments (Phoenix). Other reagents were purchased from Sigma-Aldrich. 
Bacteria Purification  
The lyophilized bacteria was suspended in 1ml PBS (1x) and cleaned by 
centrifugation at the speed of 50g for 1 minute to remove charcoal and collecting the 
supernatant containing bacteria. The supernatant was collected and washed further by 
pelleting bacteria in the centrifuge at the speed of 2000g for 15 minutes.  The pelleted 
bacteria was suspended in 1ml PBS and mixed thoroughly. Further, the above washing 
step was repeated three times. The final 1ml of bacteria in PBS solution, after 3 rounds of 
purification, was saved in small aliquots of 20 µl and frozen at -80 °C. 
Surface Functionalization  
Clean BK7 glass cover slips were coated with 1.5 nm chromium and 47 nm gold to 
prepare SPR chips. The chips were cleaned with deionized water and ethanol multiple 
times and blown dry with nitrogen gas and then cleaned by hydrogen flame. The cleaned 
chips were submerged in 1 mM PEG/PEG-COOH ethanol solution and left overnight in 
dark for 24 hrs. The overnight incubated chips were taken out and cleaned with deionized 
  
29 
water, ethanol solution multiple times and blown dry with nitrogen gas. PEG/PEG-COOH 
self-assembled monolayer (SAM) was deposited on each chip with this protocol. 
Next, the SAM coated chip was activated with 0.5 ml of freshly prepared mixture 
(1:1) of 0.1 M NHS and 0.4M EDC to produce NHS ester receptors capable of binding with 
amino group of antibodies via an amide bond. The chip was cleaned with deionized water 
and blown dry with nitrogen gas. Polyclonal anti-E.Coli O157:H7 antibody suspended in 
20mM sodium acetate (NaOAc) pH 5.5 at the concentration (30 µg/ml) optimized for 
maximum bacteria immobilization was immediately applied to NHS/EDC activated 
surfaces above and kept for about 60-90 mins.20 The chip was again cleaned by deionized 
water and blown dry with nitrogen gas. This antibodies conjugated sensor chips are ready 
for bacteria capture on SPRM setup later.  
Plasmonic Imaging and Flow Setup  
The plasmonic imaging setup is based on the Kretschmann configuration with a 
high numerical aperture objective (NA 1.49) and an inverted microscope (Olympus IX81) 
(Figure 3-1). The sensor chip was placed on the objective lens with refractive index 
matching immersion oil. A 680nm super luminescence diode (Qphotonics, Ann Arbor, MI) 
was used to excite the SPR images and a CCD camera (Pike-032B, Allied Vision 
Technologies, Newbuyport, MA) was used to record SPRM images. A FlexiPerm sample 
well was mounted on top of the antibody functionalized gold chip and filled with PBS (1x) 
buffer. The assembled gold chip was then mounted on top of the plasmonic imaging setup. 
The incident angle of the light beam was adjusted to the surface plasmon resonance angle, 
showing minimal image intensity. Sample delivery was based on a multichannel gravity 
based drug perfusion system, which flew sample solutions over the immobilized bacterial 
cells. The flow rate was 330 µl/min and the transition time between different flow 
solutions was in the range of 1-2 seconds.  
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Bacteria Immobilization  
An aliquot of frozen purified bacteria was thawed for 2 minutes, and then 20 µl of 
bacteria were added to the sensor chip. The bacteria started to attach and immobilize onto 
the sensor surface via antibody binding. After about 15-20 minutes of incubation, 
sufficient amount of bacteria were attached onto the gold chip. 1x PBS buffer was flowed 
over the chip to wash out unattached bacteria from the solution, then 5 mg/mL BSA were 
added to the chip and incubated for 1 hour to completely block the surface and prevent 
non-specific adsorption of antibody. 
Immunofluorescence Microscopy 
Following kinetics of Ab157 binding to E. Coli O157:H7 cells, fluorescence labeled 
secondary antibody at a concentration of 10 µg/ml was introduced for 5 minutes and 
washed with PBS to remove unbound secondary antibody. 
Image Collection and Processing  
All plasmonic imaging videos were collected at 3.3 fps at a pixel resolution of 
640x480. We chose an appropriate exposure time to maximize image intensity at the same 
time avoiding over exposure. Images were subtracted from the first recorded image to 
remove background noises and interference patterns. Further, images were plotted in 2D 
frequency domain using Fast Fourier Transform (FFT) conversion, and cleaned up with a 
spatial band pass filter. The cleaned images were converted back from frequency domain 
using inverse FFT. For better visualization, images were converted to scaled color images. 
Data Analyses from Images  
As mentioned in text, the plasmonic imaging intensity in each of the selected 
regions, including regions of the bacteria and bare gold chip regions, was analyzed with a 
MATLAB program. The plasmonic image intensity from each bacterium was reference 
corrected with the background bare gold regions to analyze the binding kinetics. The 
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binding kinetics was determined with the first order kinetic equation, and ka, kd and KD 
(=ka/kd) were obtained from the fitting.  
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Results and Discussion 
E. Coli O157:H7 bacteria were immobilized on the sensor chip using an anti-EColi 
O157 (antibody Ab157), which were imaged with a plasmonic imaging setup (Figure 3-1a) 
described in detail elsewhere.102–104,110,111 Briefly, the setup is based on an inverted optical 
microscope (Olympus IX81) with high numerical aperture oil immersion objectives (N.A. 
1.49). Light from a super-luminescence diode (Qphotonics, Ann Arbor, MI) with 
wavelength of 680 nm is directed onto the sensor chip, made of glass coverslip coated with 
a 47 nm thick gold film. The incident angle of light is tuned to excite surface plasmons, 
and the reflected light is imaged with the same objective together with other components, 
including a CCD imager. 
Imaging Single Bacterial Cells by Plasmonic Imaging 
The individual bacteria were imaged as distinct V-shaped patterns (Figure 3-1c), 
which match well with the positions of the bacteria in the Bright-field optical image 
(Figure 3-1b). These V-shaped patterns are caused by the scattering of surface plasmonic 
waves by the bacteria immobilized on the surface.104 The distinct patterns in the 
plasmonic image are helpful to distinguish bacterial cells from interference patterns 
originated from the optical setup, and other spatial background noises on the image. 
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Figure  
3-1. Imaging Single Cells using Plasmonic Imaging Setup  
a) Schematic of the plasmonic imaging setup using a high numerical objective and the 
immobilization of bacterial cells on top of gold chip by covalently attached antibodies.  b) 
Bright-field optical image of immobilized bacteria. c) Plasmonic image of bacteria shown 
as V-shaped diffraction patterns at positions of bacteria on bright field image. d) 
Magnified plasmonic image of a single bacterium showing clearly the V-shape diffraction 
pattern. e) 3D histogram of the bacteria in Figure 3-1d. f) Profile of the V-shaped pattern 
along the basin of V in Figure 3-1d. g) Profile of the V-shaped pattern along the middle 
axis in Figure 3-1d.  Scale bar: 2µm. Reprinted from Biosensors and Bioelectronics, Vol 63, Karan Syal, 
Wei Wang, Xiaonan Shan, Shaopeng Wang, Hong-Yuan Chen, Nongjian Tao. Plasmonic imaging of protein 
interactions with single bacterial cells. Pages 131–137, Copyright 2017, with permission from Elsevier. 
a b c 
d 
g 
e 
f 
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Figures 3-1d and 3-1e show more clearly one of the V-shaped patterns, and also 
reveal that the region of maximum intensity in each V-shaped pattern overlays one 
immobilized bacterial cell. The intensity profile along the basin of the V shaped diffraction 
pattern (X-direction) of bacterial cells show a full-width at half maximum (FWHM) of 
about 0.5 µm (Figure 3-1f). This FWHM is due to the optical diffraction limit of our 
setup.104 The intensity profile along the plasmonic wave propagation direction (Y-
direction) reveals that the intensity decays with a FWHM of about ~4 µm (Figure 3-1g). 
The intensity decay is due to the finite propagation length of surface plasmonic waves, 
which depends on the type of the metal film, and the wavelength of incident light104. We 
observe similar V-shaped patterns for all immobilized bacterial cells with no major 
differences in the decay length and FWHM for different cells. 
Binding Kinetics of Antibody to Single Cells 
Using the plasmonic imaging setup, we next imaged the binding process of Ab157 
antibody to the E. Coli O157:H7 cells immobilized on the surface. Figure 3-2a shows a 
bright-field image of 4 immobilized bacterial cells. We started the binding study by 
initially flowing 1xPBS at 330 µl/min continuously over the bacterial cells for about 2 
minutes. We then switched the flow to 1x PBS containing 10 µg/mL Ab157 to study the 
association of the antibody to the individual bacterial cells. After 3 minutes, we switched 
the flow back to 1x PBS in order to follow the dissociation process.  
Since we are interested in the association and dissociation processes of antibody 
onto the bacteria, time-differential images were obtained by subtracting the first frame 
from the subsequent frames to show changes in the image over time. Figure 3-2b1 is a 
time-differential image captured before the introduction of solution containing antibody, 
which shows weak contrast of the bacteria. If the bacteria were static, then there should 
be no contrast in the time-differential image before antibody binding taking place. The 
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observation of the small contrast is due to micro-motions of the live bacterial cells. We will 
return to this later.  
Upon exposure to the PBS containing the antibody, binding of the antibody to the 
bacteria, primarily via the O-antigen112 on the outer membrane surfaces of the bacteria, 
takes place, which is revealed as an increase in the image contrast of the individual 
bacterial cells. Figures 3-2b (2-4) show several time-differential plasmonic images of the 
association process from which detailed information of the association process can be 
obtained. For example, the images show the contrast increases for different cells are 
different, demonstrating the cell-to-cell heterogeneity that is washed out in the bulk assay. 
The images also show the increase in the intensity in the regions between the bacterial 
cells, which, as we will discuss later, is mainly due to the increase in the bulk refractive 
index as we switch the solution.  
Snapshots of the time-differential plasmonic images during the dissociation 
process are shown in Figures 3-2b (5-7), which were captured after switching the antibody-
containing solution back to PBS. During the dissociation phase, the image intensity of each 
bacterial cell decreases at a slow rate compared to the association process, which is 
expected as the antibodies dissociate from the bacterial cell. Like the association process, 
the dissociation also varies across different cells. Note also that the image intensity in the 
regions without bacteria returns to the baseline level quickly, which further supports the 
interpretation of bulk refractive index change as the origin of the intensity change in these 
regions.  
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Figure  
3-2. Imaging Binding Kinetics using Plasmonic Imaging  
a) Bright-field optical image of immobilized E. Coli O157:H7 cells. The region chosen to 
analyze the plasmonic image intensity of each bacterium is marked as a colored box in the 
bright-field image. Also shown is the background control region as a green box near the 
center of the image. b) Time-differential plasmonic images captured during different 
stages of association (b1-b4) and dissociation (b4-b7) processes. A complete plasmonic 
video of the binding kinetics is given in the supporting information. Scale bar: 2µm. 
Reprinted from Biosensors and Bioelectronics, Vol 63, Karan Syal, Wei Wang, Xiaonan Shan, Shaopeng Wang, 
Hong-Yuan Chen, Nongjian Tao. Plasmonic imaging of protein interactions with single bacterial cells. Pages 
131–137, Copyright 2017, with permission from Elsevier. 
 
The image intensity vs. time profiles obtained from the recorded image sequence 
provides detailed kinetic information of the antibody binding to the bacterial cells (Figure 
3-3). This type of plots has been widely referred to as sensorgrams, but Figure 3-3 
a                                b1                                b2                                b3 
 
 
b4                              b5                              b6                                 b7 
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represents the first sensorgrams on single bacterial cells. The sensorgrams are “noisy”, 
which is mainly due to micromotions of the bacteria. The bacterial cells in the present 
work were alive and attached to the sensor surface via relatively weak non-covalent bonds, 
so we observed frequent movement of the bacterial cells in the plasmonic images. Despite 
the micro-motions, the sensorgrams can be fit with the first order kinetics model, from 
which kinetic constants, including ka, kd and KD, for each of the bacteria cells are obtained 
(see Table 3-1). Figure 3-3 also plots the image intensity vs. time profile of a region 
between the bacteria cells, which shows only a bulk index change with no binding kinetics 
curve as observed over bacterial cells. This observation indicates that non-specific binding 
of the antibody to the sensor surface is insignificant. 
Figure  
3-3. Sensorgrams of Single Bacterial Cells Obtained by Plotting the Image Intensity Vs. 
Time  
Smooth solid lines are fits to the first order kinetics for different cells, allowing the 
determination of kinetic constants, ka, kd and KD for each of the bacteria cells. The green 
line plots the sensorgram of a region without bacteria cells, showing a sudden increase and 
decrease as the flow is switched from PBS buffer solution to sample solution, and then 
back to PBS buffer, respectively. Reprinted from Biosensors and Bioelectronics, Vol 63, Karan Syal, 
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Wei Wang, Xiaonan Shan, Shaopeng Wang, Hong-Yuan Chen, Nongjian Tao. Plasmonic imaging of protein 
interactions with single bacterial cells. Pages 131–137, Copyright 2017, with permission from Elsevier. 
Table 
3-1. Kinetics of Individual Microbial cells  
 
Validating Binding Kinetics by Control Experiments 
To further validate the plasmonic imaging of the antibody binding to bacterial cells, 
we used AlexaFlor555 labeled secondary antibody to bind to the attached primary 
antibody. Figure 3-4 shows the conventional bright field optical, time-differential 
plasmonic and fluorescence images of a sensor surface covered with multiple bacteria cells. 
The fluorescence image (Figure 3-4c) confirms that the increase in the plasmonic image 
intensity is due to the binding of the primary antibody to the bacterial cells. As an 
additional validation experiment, we used a goat anti-E. coli O145 IgG polyclonal antibody 
(Ab145) as a negative control. The exposure of E. Coli cells to Ab145 did not change the 
plasmonic image intensity (Figure 3-5), indicating that the binding kinetics of Ab157 with 
E. Coli cells were specific. 
 
 
 
 
 
 
 
Bacteria 
Association 
rate (ka) (M-1 s-
1 ) 
Dissociatio
n rate  (kd) 
(s-1 ) 
Dissociation 
Constant (KD) 
(M) 
Peak 
Plasmonic 
Image 
intensity 
Bacteria 1 5.1 x 104 6.9 x 10-4 1.3 x 10-8 97.5 
Bacteria 2 1.3 x 105 5.1 x 10-5 4.0 x 10-10 50.8 
Bacteria 3 5.1 x 104 2.1 x 10-4 4.1 x 10-9 67.0 
Bacteria 4 2.0 x 105 4.4 x 10-4 2.3 x 10-9 40.1 
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Figure  
3-4. Using Fluorescent Imaging to Validate Binding Kinetics 
a) Bright-field optical image of bacteria immobilized on a gold chip. b) Time-differential 
plasmonic image showing V-shape diffraction patterns corresponding to the individual 
bacterial cells in Fig. 4a. c) Fluorescence image after adding secondary antibody labelled 
with Alexaflor555. Scale bar: 5 µm. Reprinted from Biosensors and Bioelectronics, Vol 63, Karan Syal, 
Wei Wang, Xiaonan Shan, Shaopeng Wang, Hong-Yuan Chen, Nongjian Tao. Plasmonic imaging of protein 
interactions with single bacterial cells. Pages 131–137, Copyright 2017, with permission from Elsevier. 
a 
b 
c 
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a                                                                    
 
b 
 
Figure  
3-5. Binding Kinetics of Negative Control  
a) Bright-field optical image of immobilized E. Coli O157:H7 cells. Scale bar: 2 um. b) 
Sensorgrams of single bacterial cells on flowing the negative control antibody Ab145. 
There is no increased plasmonic image intensity observed for bacterial cells compared to 
the background signal. The data shows that the binding of the bacteria with the antibody 
Ab157 was specific. Reprinted from Biosensors and Bioelectronics, Vol 63, Karan Syal, Wei Wang, Xiaonan 
Shan, Shaopeng Wang, Hong-Yuan Chen, Nongjian Tao. Plasmonic imaging of protein interactions with single 
bacterial cells. Pages 131–137, Copyright 2017, with permission from Elsevier. 
 
 
  
41 
The results discussed above demonstrate a new capability for studying the binding 
kinetics of single bacteria. Compared to the conventional SPR approach which studies a 
layer of many bacterial cells immobilized on a sensor surface,19,20 the single bacteria 
binding kinetics analysis capability can discriminate non-specific binding taking place on 
the regions of the sensor surface without bacteria cells. More importantly, it opens up the 
possibility of detecting individual microbes in mixed communities, biofilms as well as 
microbe-infected patient samples. We demonstrate below kinetics analysis of multiple 
bacterial cells and cell-to-cell heterogeneity. 
Quantifying Bacterial Surface Heterogeneity 
 Figure 3-6a and 3-6b show the distributions of ka and kd values, respectively. The 
data were obtained by fitting the sensorgram of each bacterial cell (33 bacteria cells) with 
the first order binding kinetics model. Although the number of bacterial cells was limited, 
the data shows 2 orders of magnitude variability in ka and kd. KD was obtained from the ka 
and kd values with the relation, KD=kd /ka (Figure 3-5c). Unlike the distributions of ka and 
kd, the distribution of KD has a center, which is near 3.9 nM. This KD value is close to the 
previously reported values in literature.19 However, the presence of 4 orders of magnitude 
in KD conveys the heterogeneity in how an antibody might interact with individual cells.  
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Figure  
3-6. Distribution of Binding Constants.  
(a) Distributions of association rate, ka (a), dissociation rate, kd (b), dissociation constant, 
KD, (c) observed on various bacteria. The large variability in the observed kinetics 
conveying cell-cell heterogeneity in Ab157 interacting with bacterial cells. Reprinted from 
Biosensors and Bioelectronics, Vol 63, Karan Syal, Wei Wang, Xiaonan Shan, Shaopeng Wang, Hong-Yuan 
Chen, Nongjian Tao. Plasmonic imaging of protein interactions with single bacterial cells. Pages 131–137, 
Copyright 2017, with permission from Elsevier. 
 
 
We also obtained distribution (Figure 3-7) of the plasmonic image intensity 
measured at the end of association phase from various bacterial cells. Since the plasmonic 
intensity is proportional to the mass density change of the sensor surface, the data reflects 
the distribution in the expression levels of O-antigen on the outer membranes of the 
bacterial cells. We performed statistical analysis and found no obvious correlations 
between the measured O-antigen expression levels, ka, kd and KD and the physical 
parameters, including length and size, of the bacteria (Table 3-2).  
 
 
 
a                                              b                                               c 
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Figure  
3-7 Distribution of the Plasmonic Image Intensity Measured at the End of Association 
Phase for Various Bacterial Cells.  
Reprinted from Biosensors and Bioelectronics, Vol 63, Karan Syal, Wei Wang, Xiaonan Shan, Shaopeng Wang, 
Hong-Yuan Chen, Nongjian Tao. Plasmonic imaging of protein interactions with single bacterial cells. Pages 
131–137, Copyright 2017, with permission from Elsevier. 
 
Table 
3-2. Correlation of Kinetics Parameters with Physical Attributes and Plasmonic 
Imaging Parameters 
All 
Bacteria ka kd KD 
Plasmonic 
Intensity Length Breadth Area 
Peak V-
shape 
Intensity 
ka 1.00 0.17 
-
0.47 0.27 0.04 0.34 0.21 -0.10 
kd 0.17 1.00 0.24 0.01 -0.32 -0.31 -0.29 -0.42 
KD 
-
0.47 0.24 1.00 -0.29 -0.38 -0.70 -0.37 -0.32 
Plasmonic 
Intensity 0.27 0.01 
-
0.29 1.00 0.52 0.06 0.36 -0.02 
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We believe that the reason for the observed cell-to-cell variability is the O-antigen 
on the surfaces of the bacteria,112 which is the target for the antibody. Studies have shown 
large variations in the chain length of O-antigen, which give E. Coli distinct surface 
morphologies (smooth, semi-rough and rough).113 This variation in chain length exists 
owing to Wzz and Wzy proteins, which are responsible for modulating the O-antigen chain 
lengths. Wzz assembles the O-antigen around a specific modal length whereas Wzy 
assembles O-antigen to a stochastic length.114,115 These variations in O-antigen may be the 
primary reason for the observed cell-to-cell variability in the antibody binding kinetics. 
The wide distributions in kinetic constants indicate the natural phenotypic 
diversity in a bacterial population. Capturing this diversity is important, especially 
because microbial sub-populations with variable phenotypic characteristics are known to 
play an important role in microbial evolution and antibiotic resistance.116 The traditional 
bulk assays that measure average KD of a large number of bacteria cells could be 
misleading, especially when a species evolves and sub-populations emerge. In contrast, 
the present plasmonic imaging method can provide quantitative analysis of ligand 
interactions with individual live bacteria, which represents an unprecedented capability 
for studying the role of physiological heterogeneity in microbial population behaviors and 
providing new insights into microbial diversity arising from the rapid replication of 
bacteria.  
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Conclusion 
We have described a plasmonic imaging method for studying the interaction 
kinetics between biomolecules and individual bacterial cells. The method is label-free, 
quantitative and in real time. Using the method, we have measured the kinetics of an 
antibody binding to single E. Coli O157:H7 bacterial cells. The mean values of the 
measured kinetic constants (e.g., KD) are consistent with the reported literature values 
obtained from bulk assays. However, the present method revealed large cell-to-cell 
variations in binding kinetics with kinetic constants distributed over several orders of 
magnitude. These results are direct evidence that large heterogeneity in the binding 
capability of bacteria with external ligands naturally exists in a bacterial population. Such 
heterogeneity has been hypothesized as an important mechanism for evolution and fitness 
in microbes. We anticipate that this method will improve the understanding of bacterial 
behaviors, such as pathogenesis and immune escape of virulent microbes, action and 
efficacy of antimicrobial peptides in acting on a microbial population and binding 
affinities of humanized antibodies against microbes for future drug therapies. 
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ANTIMICROBIAL SUSCEPTIBILITY TEST WITH PLASMONIC IMAGING AND 
TRACKING OF SINGLE BACTERIAL MOTIONS ON NANOMETER SCALE 
 
Antimicrobial susceptibility tests (ASTs) are important for confirming 
susceptibility to empirical antibiotics and detecting resistance in bacterial isolates. 
Currently, most ASTs performed in clinical microbiology laboratories are based on 
bacterial culturing, which take days to complete for slowly growing microorganisms. A 
faster AST will reduce morbidity and mortality rates and help healthcare providers 
administer narrow spectrum antibiotics at the earliest possible treatment stage. We report 
the development of a non-culture-based AST using a plasmonic imaging and tracking (PIT) 
technology. We track the motion of individual bacterial cells tethered to a surface with 
nanometer (nm) precision and correlate the phenotypic motion with bacterial metabolism 
and antibiotic action. We show that antibiotic action significantly slows down bacterial 
motion, which can be quantified for development of a rapid phenotypic-based AST.  
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Introduction 
Acute infections, such as sepsis, affect over a million people every year, leading to 
mortality rates of 30-50%.30,117 For septic and other day-to-day patients infected with 
bacterial pathogens, antimicrobial susceptibility testing (AST) is used to predict the in vivo 
success or failure of the chosen antibiotic therapy along with diagnosing antibiotic 
resistant bacteria. Current culture-dependent AST technologies are slow with a 
turnaround of 1-3 days (Chapter 2), thus posing a risk on the patient’s life.118 A rapid AST 
will help generate antibiotic susceptibility profiles at the earliest possible stages of 
infection, identify antibiotic-resistant bacterial isolates, and allow narrow-spectrum or 
personalized administration of antibiotics.  
Antimicrobial susceptibility testing methods currently used in clinical 
microbiology and commercial diagnostic labs include culture-dependent disk diffusion 
and broth dilution tests (Chapter 2) which may take up to two days to complete.9,32,119 
Many emerging technologies (Chapter 2) efforts have been devoted to develop faster AST 
technologies in recent years, several of which are based on characterizing the physical 
features of bacterial growth, such as the number, size, and length of bacterial 
cells.42,46,49,54,55,58,89 Another approach is to use imaging technologies to analyze the 
changes in imaging area54,55,58,89 or fluorescent signal42,120 associated with the growth of 
the bacterial cells. This imaging approach has achieved some success, especially in 
susceptibility testing of single cells present within polymicrobial mixtures of complex 
clinical samples, including broncho alveolar lavage specimens collected from patients with 
ventilator-assisted pneumonia41 and urine samples spiked with bacterial cells.55 However, 
the accuracy of these imaging approaches requires further improvement.40 Moreover, 
most of these approaches still rely on culturing, which is not universally applicable, 
especially for slow-growing, difficult-to-culture, or uncultivable bacteria. 121 
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More recently, future technologies such as Atomic Force Microscope (AFM) 
cantilevers (Chapter 2) have been used to detect bacterial cell metabolism and perform 
rapid antimicrobial susceptibility testing.44,77,78 The method immobilizes several hundred 
bacterial cells on a cantilever and detects cantilever deflections associated with the micro-
motions of the bacterial cells immobilized on the cantilever. The correlation between the 
micro-motions and the viability (life or death) has been studied for both prokaryotic and 
eukaryotic cells recently.44,77,79,122,123 The AFM cantilever approach does not resolve the 
micro-motions of each individual cell which might be useful for poly-microbial samples 
and finding resistant sub-populations of bacteria. 
Here we report a plasmonic imaging23,111 and tracking (PIT) method to quantify the 
motions of single bacterial cells with nanometer resolution and correlate the nano-motion 
with bacterial metabolism and antibiotic action. To demonstrate the plasmonic tracking 
approach, we study Escherichia coli O157:H7, a bacterial pathogen implicated in food-
borne illness outbreaks, as a model strain.24 For these proof-of-concept studies, we use 
polymyxin B, a bactericidal antibiotic which permeabilizes the outer membrane of Gram-
negative bacilli.124 We also show the feasibility of this approach to a clinical relevant strain 
Uropathogenic Escherichia coli CFT073 (UPEC), which is implicated in 65%-75% of 
urinary tract infections (UTIs).27 We have imaged the individual bacterial cells, tracked 
their nano-motion, analyzed the correlation between their viability and the nano-motion, 
and examined the PIT technique as a rapid antimicrobial susceptibility testing method. 
Materials and Methods 
Materials 
Lyophilized bacterial pellets of E. coli O157:H7 (ATCC 43888) were purchased 
from Fisher Scientific. UPEC E. coli strain CFT073 was purchased from ATCC. Affinity-
purified goat anti-E. coli O157:H7 IgG polyclonal antibodies were purchased from 
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Kirkegaard and Perry Laboratory Inc. (Gaithersburg, MD), suspended in 1 ml PBS (1X), 
and stored in aliquots at -20°C. Polymyxin B (PMB) was purchased from Sigma-Aldrich 
and dissolved in 1X PBS at a stock concentration of 10 mg/ml. PMB was stored in dark at 
2-8°C according to manufacturer’s instruction. 1-Mercapto-11-undecyl hexa(ethylene 
glycol) (PEG) and carboxyl-terminated hexa(ethylene glycol) undecane thiol (PEG-COOH) 
were purchased from Nanoscience Instruments (Phoenix, AZ). Other reagents were 
purchased from Sigma-Aldrich. 
Preparation and Growth of Bacteria  
The lyophilized bacteria were suspended in PBS centrifuged at the speed of 50 x g 
for 1 min to pellet the charcoal. The supernatant containing bacteria was collected and 
centrifuged at 2000 x g for 15 min to pellet the bacteria. The bacterial pellet was re-
suspended in 1 ml 1X PBS and mixed thoroughly. The final 1 ml of bacteria in PBS solution, 
after 3 rounds of purification, was collected in small aliquots of 20 µl and frozen at -80°C 
adding 5% glycerol. Similarly, E. coli strain CFT073 strain was mixed 5% glycerol and 
frozen in smaller aliquots at -80°C. 
An aliquot of frozen E. coli O157:H7 or E. coli CFT073 strain was thawed and used 
to inoculate 10 ml of LB medium. E. coli O157:H7 cultures were prepared by diluting the 
overnight culture (grown at 37°C) into fresh LB medium to a concentration of 107 colony 
forming units (CFU)/ml and continuing growth at 37°C with gentle rotary mixing until the 
cultures reached mid-logarithmic phase of growth. Bacterial cells were collected by 
centrifugation at 2000 x g for 15 min and re-suspended in 1 ml PBS (1X).    
Surface Functionalization 
Clean BK7 glass cover slips were coated with 1.5 nm chromium and 47 nm gold and 
used as SPR sensing chips. The chips were cleaned with deionized water and ethanol for a 
few times, dried with nitrogen gas, and then cleaned by hydrogen flame. For antibody 
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surface, the cleaned chips were submerged in 1 mM PEG/PEG-COOH ethanol solution 
and left in the dark for 24 h to coat a PEG/PEG-COOH self-assembled monolayer (SAM) 
on each chip. For APTES surface, the cleaned chips were submerged in 1 mM PEG solution 
and left in the dark for 24 h to coat a PEG SAM on the chips. The coated chips were then 
cleaned again with washes in deionized water and ethanol and subsequently dried with 
nitrogen gas.  
To attach antibodies next, the PEG/PEG-COOH SAM-coated chips were activated 
with 500 μl of a freshly prepared mixture of 0.1 M NHS and 0.4M EDC in 1:1 ratio to 
produce NHS ester receptors, which react with the primary amine groups on the 
antibodies via an amide bond. Chips with activated PEG/PEG-COOH SAM were cleaned 
with deionized water and blown dry with nitrogen gas. Polyclonal anti-E. coli O157:H7 IgG 
antibodies dissolved in 20 mM sodium acetate (NaOAc), pH 5.5 (30 µg/ml) were 
immediately applied to the NHS/EDC-activated surfaces and incubated for 60-90 min. 
The antibody-coated chips were again cleaned with deionized water and dried with 
nitrogen gas prior bacterial cell capture on the PIT setup.  
To attach the APTES linker to the sensor surface, the PEG SAM-coated sensors 
were activated with 100 μl of a freshly prepared 1% APTES in in ethanol (with 5% water) 
for 2 minutes. The APTES linked sensor chips were again cleaned with deionized water 
and dried with nitrogen gas prior bacterial cell capture on the PIT setup.  
Plasmonic Imaging and Flow Setup 
The plasmonic imaging setup is based on the Kretschmann configuration with a 
high numerical aperture objective (NA 1.49) and an inverted microscope (Olympus IX-81) 
(Fig. 1).103,104,110 The sensor chip was placed on the objective lens with refractive index 
matching immersion oil. A 680 nm super luminescent diode (Qphotonics, Ann Arbor, MI) 
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was used to excite the SPR images, and a CCD camera (Pike-032B, Allied Vision 
Technologies, Newbuyport, MA) was used to record PIT images.  
A FlexiPerm reusable well (SARSTEDT) was mounted on top of the antibody-
functionalized gold chip and filled with 500 µl PBS (1X) buffer. The assembled gold chip 
was then mounted on top of the plasmonic imaging setup. The incident angle of the light 
beam was adjusted to the surface plasmon resonance angle, revealing minimal image 
intensity.  
Bacterial Immobilization 
Bacterial cells (20 µl) were added to the sensor chip and tethered onto the sensor 
surface via non-covalent antibody binding. After 10-15 min incubation at room 
temperature, bacterial cells were sufficiently attached to the gold chip. PBS buffer was 
subsequently flowed over the chip to remove unattached bacterial cells. 
Image Collection and Processing 
All plasmonic imaging sequences were collected at 106 fps at a pixel resolution of 
640x480. We chose an appropriate exposure time to maximize image intensity and avoid 
over exposure. Images were recorded in either transmitted or plasmonic imaging mode 
for various time durations. 
Sample Addition 
Multiple sample solutions, including LB medium or PBS, were added to the 
bacterial cells via a gravity-based multichannel drug perfusion system (Warner 
Instrument, Hamden, CT). The drug perfusion system flew sample solutions over the 
immobilized bacterial cells at a flow rate of 330 µl/min with the transition time between 
different flow solutions in the range of 1-2 sec. The flow system was stopped and stabilized 
for 5 min before adding PMB, streptomycin or glucose. To deliver antibiotics, we pipetted 
small volumes of antibiotics into the Flexiperm well mounted on the microscope. 
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Data Analyses from Images  
We chose small time durations of about 20 sec from the videos to analyze our data 
and to avoid the influence of focus drift on nano-motion analysis. The images were 
processed using custom-written MATLAB programs and Image J scripts.   
Bacterium – Plasmon Surface Z-Distance Tracking and Z-Movement 
Calculation 
The plasmonic image intensity was calculated by obtaining averaged intensity within a 
fixed area around the bacterial cell using the bare gold chip regions as reference. The z-
distance of the bacterial cell above the sensor surface was then calculated from the 
plasmonic image intensity (Iz) with a calibrated curve, given by 
𝐼𝑧 = 𝐼0 exp(−
∆𝑧
𝐿
), (Eq. S1) 
Where 𝐼0  is a constant, Δ𝑧 is the z displacement of a bacterial cell, and L is the decay 
constant. The decay constant was determined to be ~95.8 nm.125 Using the above 
calibration, we calculated the error in the z-displacement to be about 0.1 nm.   
We define “z-movement” as the relative z-distance, where the mean bacterium-
plasmon surface z-distance in a given time duration is subtracted from the z-distance at a 
given moment. Further “amplitude” is defined as the standard deviation of the z-
movement for a given period of time. 
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Results and Discussion 
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Figure 4-1. (a) Setup and principle of plasmonic imaging and tracking of bacterial cells 
tethered to a gold-coated glass sensor chip. p-polarized light is directed onto the sensor 
chip to create surface plasmons on the gold surface, and the reflected light is detected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  
4-1. Setup of Plasmonic Imaging and Tracking 
(a) Setup and principle of plasmonic imaging and tracking of bacterial cells tethered to 
a gold-coated glass sensor chip. P-polarized light is directed onto the sensor chip to 
create surface plasmons on the gold surface, and the reflected light is detected with a 
CCD to form plasmonic images. Bright field transmission images of the bacterial cells 
are also simultaneously obtained with the same objective. (b) Bright field image of a 
tethered bacterial cell. (c) Simultaneously-recorded plasmonic image of the bacterial 
cell. Scale bar:  2 µm. 
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Quantification of Z-Direction Motion 
Figure 4-1a shows the PIT setup built on an optical microscope with a high numerical 
aperture objective.103,104,110 A sensor chip, made of a glass coverslip coated with 47 nm thick 
gold film, is placed on the microscope sample stage. Light with a wavelength of 680 nm 
from a super luminescent diode is directed onto the film via the objective. By tuning the 
incident angle, surface plasmons are excited on the gold surface, and the reflected light is 
imaged with a CCD imager. The E. coli O157:H7 cells, tethered on a sensor chip via 
antibody coupling, scatter the surface plasmonic wave, leading to parabolic-shaped 
patterns in the plasmonic image.23 Figures 4-1b and 4-1c show the transmission and 
plasmonic images of a bacterial cell, where the vertex of the parabolic pattern in the 
plasmonic image is the location of the cell shown in the simultaneously recorded 
transmission images.   
We have analyzed the motion of the bacterial cells in the transmission and the 
plasmonic images. The transmission image contrast of the bacterial cells appears to be 
constant, but the plasmonic image contrast fluctuates significantly. To show the contrast 
fluctuation of the plasmonic image, we created differential plasmonic images by 
subtracting the lowest contrast image from all of the images. Figure 4-2a shows a few 
snapshots of the differential images, which reveal large fluctuations in the plasmonic 
image contrast of a bacterial cell. This image contrast fluctuation is due to the nano-
motion of the bacterial cell normal to the z sensor chip (z direction),126 which is due to the 
surface plasmon intense evanescent electric field, which decays exponentially from the 
surface into the bulk solution. Consequently, the scattering of the plasmonic waves by the 
bacterial cell decreases exponentially with the distance (z) between the cell and the sensor 
surface. We have shown previously that the plasmonic image contrast change ( I/I) of a 
particle is related to the distance change (z), by I/I=exp(- z/95.8 nm).125 Using this 
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relation, we have determined the nano-motion of the bacterial cell in z direction, which is 
shown in Figure 4-2b. The magnitude of the nano-motion of the bacterial cell above the 
plasmon surface, is less than 10 nm with an average motion magnitude of ~ 6 nm, which 
cannot be detected in the traditional transmission optical image. As a control experiment, 
we tracked the nano-motion of a dead bacterial cell (Figure 4-2c) and observed a much 
smaller magnitude of nano-motion (~ 0.50 nm). The data demonstrate the capability of 
the plasmonic imaging technology for tracking the motion of individual bacterial cells with 
sub-nm precision. 
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Correlation Between Nano-motion and Bacterial Metabolism 
As supported by further evidence shown below, the bacterial nano-motion is 
related to the bacterial metabolism. For live cells, bacterial metabolism is associated with 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  
4-2. Quantifying Z-direction Nano-motion of Bacterial Cells using Plasmonic Images 
(a) Snapshots of bacterial z nano-motion revealed by the varying plasmonic image 
contrast. (b) z-Distance between bacterium and plasmon surface vs. time plot with an 
average nano-motion magnitude of ~ 6 nm. (c) z-Distance between bacterium and 
plasmon surface plot of a dead bacterial cell (no motion) showing an average motion 
magnitude of 0.50 nm. Scale bar (2 µm). Reprinted with permission from Syal, K.; Iriya, R.; Yang, 
Y.; Yu, H.; Wang, S.; Haydel, S. E.; Chen, H.-Y.; Tao, N. Antimicrobial Susceptibility Test with Plasmonic 
Imaging and Tracking of Single Bacterial Motions on Nanometer Scale. ACS Nano 2015, 10, 845–852. 
Copyright 2017 American Chemical Society. 
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cytoplasmic membrane transport,44 cytoplasm fluidity,127 and modifications of membrane 
lipid composition in response to environmental changes,128 all of which can cause micro-
motion of the cells.  In the present system, the bacterial cells are attached to the surface 
via antibodies, involving soft non-covalent bonds that prevent large-scale motions, but 
allow nano-motion of the bacterial cells.  
For better clarity, we define “z-movement” as the relative z-distance, where the 
mean bacterium-plasmon surface z-distance in a given time duration is subtracted from 
the z-distance at a given moment. Further “amplitude” is defined as the standard deviation 
of the z-movement for a given period of time. 
The images shown in Figure 4-2 were obtained using 1x PBS as the medium. To 
ensure that the bacterial cells attached to the surface are metabolically active, we changed 
the buffer from 1X PBS to Luria Broth (LB) culture medium and incubated the cells for 
approximately 20 minutes. After incubation in LB, bacterial cells grew, as evident by the 
elongation of cells detected in the transmission images. Comparisons of the nano-motion 
of live bacterial cells in 1X PBS and LB revealed similar amplitudes (Figure 4-3).  
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Figure  
4-3.  Z-movement in 1X PBS and LB medium  
a) Blue trace shows z-movement of a typical bacterial cell in 1X PBS buffer. Orange trace 
shows z-movement of a typical bacterial cell incubated in LB medium. The z-movements 
in both 1X PBS and LB medium are comparable with amplitudes (standard deviation of z-
movement) of 2.31 nm and 2.22 nm, respectively. Pink traces show that detectable motion 
in the bacterial-free area (system noise) are negligible in both cases. B) Transmitted image 
of a bacterial cell in 1X PBS with a recorded length of 4.81 m. Scale bar (1 µm). c) 
Transmitted image of a bacterial cell in LB medium with a recorded length of 5.06 m. 
Scale bar (1 µm). Reprinted with permission from Syal, K.; Iriya, R.; Yang, Y.; Yu, H.; Wang, S.; Haydel, S. 
E.; Chen, H.-Y.; Tao, N. Antimicrobial Susceptibility Test with Plasmonic Imaging and Tracking of Single 
Bacterial Motions on Nanometer Scale. ACS Nano 2015, 10, 845–852. Copyright 2017 American Chemical 
Society. 
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Changes in Nano-motion on Antibiotic Action 
We then studied the effects of antibiotics on the nano-motion of live bacterial cells 
by adding polymyxin B (PMB) to 1X PBS to reach a final concentration of 500 μg/ml. PMB 
is a bactericidal antibiotic which kills Gram-negative bacteria by permeabilizing the outer 
membrane.124 At high concentrations, such as 500 μg/ml used in this study, PMB also 
depolarizes the cytoplasmic membrane, causing ion-permeable pores in the cell 
envelope.124 Within a few seconds after adding the antibiotic, there was a marked decrease 
in the z-movement of the bacterial cell from about ±3 nm to about ±1 nm as shown in 
Figure 4-4a. We further observed that after a few minutes, the bacterial cell z-movement 
reached a baseline value of ±0.5 nm. This decrease in bacterial nano-motion can be 
attributed to bactericidal activity of PMB, which has been observed at a concentration of 
20 μg/ml.124 We used 25X the bactericidal concentration in this project to ensure complete 
loss of cellular viability.  Bactericidal activity was also observed by comparing cellular 
morphology after adding antibiotics, where decreases in bacterial cell length at a high 
antibiotic concentration were visualized (Figure 4-5). The decrease in bacterial cell length 
has been previously correlated to cell lysis and cell death after the addition of polypeptide 
antibiotics.13 We validated the correlation between the decreases in nano-motion and 
change of the bacterial metabolic state by replacing the antibiotic-containing PBS with LB 
medium (lacking PMB) on the sensor chip. We observed no further change in the bacterial 
nano-motion after incubating in LB medium, indicating irreversible loss of metabolic 
activity after the treatment with PMB. We subsequently collected a small sample volume 
from the above sensor chip and subjected it to culturing overnight in LB medium. We 
observed no growth of bacterial cells after overnight incubation, thus confirming bacterial 
cell death and bactericidal activity of the PMB antibiotic. 
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Figure  
4-4. Z-movement of a Bacterial Cell in Different Mediums 
(a) Effect of antibiotic polymyxin B at a concentration of 500 µg/ml on z-movement of 
a bacterial cell. (b) Control experiments comparing z-movement in PBS (blue) and on 
injections of 2% glucose (purple), 1X PBS (blue), and antibiotic (red). (c) Amplitude 
analysis of z-movements in different media. Reprinted with permission from Syal, K.; Iriya, R.; 
Yang, Y.; Yu, H.; Wang, S.; Haydel, S. E.; Chen, H.-Y.; Tao, N. Antimicrobial Susceptibility Test with 
Plasmonic Imaging and Tracking of Single Bacterial Motions on Nanometer Scale. ACS Nano 2015, 10, 
845–852. Copyright 2017 American Chemical Society. 
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Figure  
4-5 Observing Cell Death by Transmitted Images  
a) Bacterial cell 1 compared in size before (a1) and after adding antibiotics (a2). The 
bacterium length shrinks after adding antibiotics, which indicates possible cell death. B) 
Bacterial cell 2 compared in size before (b1) and after adding antibiotics (b2). The 
bacterium length shrinks after adding antibiotics, which indicates possible cell death. 
Subsequent culturing experiments confirmed the death of these cells. Scale bar (1 µm). 
Reprinted with permission from Syal, K.; Iriya, R.; Yang, Y.; Yu, H.; Wang, S.; Haydel, S. E.; Chen, H.-Y.; Tao, 
N. Antimicrobial Susceptibility Test with Plasmonic Imaging and Tracking of Single Bacterial Motions on 
Nanometer Scale. ACS Nano 2015, 10, 845–852. Copyright 2017 American Chemical Society. 
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Furthermore, we injected antibiotic with a sub-bactericidal concentration (0.5 
ug/ml), followed by a 5x bactericidal concentration injection. At sub-bactericidal 
concentrations we did not observe changes in the nano-motion after 20 minutes. However, 
after injecting bactericidal concentrations we observed a significant decrease in nano-
motion, which validates the correlation between the decrease in nano-motion and change 
of the bacterial metabolic state. (Figure 4-6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  
4-6. Z-movement in 1x PBS and Different Concentrations of Antibiotic  
Blue trace (left) shows Z-movement of a E. coli O157:H7 cell on the sensor chip in 1X PBS 
buffer. Green trace (middle) show that introducing sub-bactericidal concentrations (0.5 
µg/ml) of antibiotic PMB does not change the Z-movement. However, introducing the 
antibiotic at 5x bactericidal concentration (100 µg/m) leads to a large decrease in Z-
movement (red trace). Reprinted with permission from Syal, K.; Iriya, R.; Yang, Y.; Yu, H.; Wang, S.; 
Haydel, S. E.; Chen, H.-Y.; Tao, N. Antimicrobial Susceptibility Test with Plasmonic Imaging and Tracking of 
Single Bacterial Motions on Nanometer Scale. ACS Nano 2015, 10, 845–852. Copyright 2017 American 
Chemical Society. 
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We performed a further control experiment by injecting glucose into the PBS – 
bacteria mixture. Glucose is a chemoattractant and represents an energy source for the 
bacteria. As shown in Figure 4-4b, after the injection of 2% glucose, the nano-motion of 
the bacteria increased slightly. After subsequently eliminating glucose in the 1X PBS 
medium, the amplitude of the nano-motion, measured over 1s windows for 20s videos, 
decreased back to the level prior to the injection of glucose (Figure 4-4c). The positive 
correlation between glucose injection and z-movement strongly supports that bacterial 
cell nano-motion originates from metabolic activity rather than Brownian motion. 
Conversely, we observed a decrease in bacterial nano-motion only when PMB was added 
at the bactericidal concentration of 75 μg/ml, thus indicating that the decrease in nano-
motion is specific to antibiotic action. Antibiotic activity was also observed by the 
transmitted microscope image, which shows a visible decrease in cell length after the 
addition of PMB. We subsequently subjected the experimental sample to overnight 
culturing in LB medium and observed no bacterial growth, thus validating PMB-induced 
cell death (Figure 4-5). 
Figures 4-7 (a1-a3) show additional examples of the nano-motion of several 
bacterial cells before and after antibiotic injection, revealing similar reductions in the 
nano-motion caused by PMB. The magnitude of the nano-motion varies from cell to cell, 
both before and after the antibiotic injection. We attribute these variations to bacterial 
metabolic activities or interactions of individual bacterial cells with antibodies present on 
the sensor chip.  
Power Spectral Analysis of Nano-motion 
We performed power spectral density (PSD) analysis on the nano-motion. For 
antibiotic-treated bacterial cells where the z-movement is small, the PSD shows weak 
frequency dependence similar to the background noise (Figure 4-7b, red trace). In contrast, 
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the PSD of the live bacterial cells is significantly larger and depends on frequency 
according to 1/fα frequency with 1<α<2 for frequencies between 1 to 50 Hz (Figure 4-7b, 
blue trace).  Below 1 Hz, the PSD is not reliable because of the mechanical drift of the 
optical system, and above 50 Hz, the z-movement decreases to the background noise level. 
This PSD feature is similar to that of AFM cantilever defection associated with multiple 
bacterial cells attached to the cantilever.78   
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Figure  
4-7 Power Spectral Analysis and Z-movement Analysis of Different Bacterial Cells 
(a) z-movement of individual bacterial cells before and after antibiotic treatment. (b) 
PSD of z-movement of individual bacterial cells before and after antibiotic treatment.  
Reprinted with permission from Syal, K.; Iriya, R.; Yang, Y.; Yu, H.; Wang, S.; Haydel, S. E.; Chen, H.-Y.; 
Tao, N. Antimicrobial Susceptibility Test with Plasmonic Imaging and Tracking of Single Bacterial Motions 
on Nanometer Scale. ACS Nano 2015, 10, 845–852. Copyright 2017 American Chemical Society. 
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Statistics on a Bacterial Population 
Figure 4-8 presents the amplitude histograms of 31 individual bacterial cells before 
and after antibiotic treatment. The amplitude has been calculated as the standard 
deviation of the z-movement for a period of 20 sec. 
Before antibiotic treatment, there was a large variation in the amplitudes of the 
nano-motion of the bacterial cells. A few cells exhibited low amplitude nano-motion before 
antibiotic addition and appeared to be tethered strongly to the surface. After antibiotic 
treatment, the amplitude of nano-motion for almost all of the bacterial cells decreased 
(Figure 4-8a). However, for those cells with low initial amplitudes, the decreases in nano-
motion after antibiotic treatment are small, which are understandable since the strong 
 
 
 
 
 
 
 
 
 
Figure  
4-8. Statistical Analysis of Amplitude Analysis Before and After Antibiotic  
(a) Histograms of amplitude of individual bacterial cell nano-motions before and after 
antibiotic addition. (b) Distribution of amplitudes before and after the addition of 
antibiotic. The large difference conveys statistically-significant decreases in bacterial 
motion after the addition of antibiotics.  Reprinted with permission from Syal, K.; Iriya, R.; Yang, 
Y.; Yu, H.; Wang, S.; Haydel, S. E.; Chen, H.-Y.; Tao, N. Antimicrobial Susceptibility Test with Plasmonic 
Imaging and Tracking of Single Bacterial Motions on Nanometer Scale. ACS Nano 2015, 10, 845–852. 
Copyright 2017 American Chemical Society. 
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tethering restricts motion. Statistical analysis (student t-test) revealed that the mean 
amplitude value for all bacterial cells is significantly different before and after antibiotic 
treatment (p = 2.66e-06) (Figure 4-8b).  
Testing Universality of Nano-motion AST 
We further demonstrated the applicability of this technology to UTI infections by 
extending it to other clinically relevant strains.  We immobilized the UPEC strain on the 
sensor using the (3-Aminopropyl)-triethoxysilane (APTES) linker, rather than using the 
antibody immobilization for the Escherichia coli O157:H7 study described above. We 
studied the nano-motion changes as antibiotic PMB acted on bacterial cells at a 
bactericidal concentration of 1 mg/ml (Figure 4-9a). We observed a decrease in bacterial 
nano-motion when PMB was added indicating that the decrease in nano-motion is specific 
to antibiotic action. Subsequent overnight culturing of experimental sample in LB medium 
led to no bacterial growth, thus validating PMB-induced cell death.  We also applied the 
plasmonic tracking and imaging technology to another antibiotic, streptomycin, and 
observed decrease in the nano-motion in the bacterial cells in PBS supplemented with LB 
media, after adding streptomycin at a bactericidal concentration of 1mg/ml122,129 (Figure 
4-9b). These experiments indicate that the methods may be used for different bacterial 
strains and different antibiotics. To fully establish the present method for rapid AST in 
clinical settings, additional and more comprehensive tests will still be needed in the future. 
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Figure  
4-9. Z-movement Changes in Different Conditions 
a) 1x PBS and Antibiotic for UPEC strain. Blue trace (left) shows Z-movement of a bacterial 
cell of UPEC strain immobilized with APTES on a sensor chip in 1X PBS buffer. Red trace 
shows Z-movement after injecting 1 mg/ml polymyxin B antibiotic. The large decrease in 
the nano-motion is due to bactericidal action of antibiotic and subsequent over-night 
culturing experiments confirmed the death of the bacteria. b) Z-movement for antibiotic 
Streptomycin for E. coli O157:H7 Blue trace (left) shows Z-movement of a bacterial cell in 
0.4x LB media. Red trace shows Z-movement after injecting 1mg/ml streptomycin 
antibiotic. The decrease in in nano-motion (Z-movement) correlates to bactericidal action 
of antibiotic and subsequent over-night culturing experiments confirmed the death of the 
bacteria.  Reprinted with permission from Syal, K.; Iriya, R.; Yang, Y.; Yu, H.; Wang, S.; Haydel, S. E.; Chen, 
H.-Y.; Tao, N. Antimicrobial Susceptibility Test with Plasmonic Imaging and Tracking of Single Bacterial 
Motions on Nanometer Scale. ACS Nano 2015, 10, 845–852. Copyright 2017 American Chemical Society. 
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Conclusions 
In summary, we have demonstrated a plasmonic imaging technique to track the real-time 
motion of bacterial cells attached to a sensor surface with sub-nanometer detection limits. 
The detected nanometer-scaled motion of bacterial cells is a signature of metabolic activity 
and is correlated with viability. Upon exposure of the bacteria to high bactericidal 
concentrations of the PMB antibiotic, the nano-motion decreases substantially, thus 
revealing lethality. Despite the large variability among different cells, antibiotic-induced 
reduction of bacterial nano-motion is a robust and statistically significant phenomenon. 
These results promise development of a rapid antibiotic susceptibility testing method that 
does not require culturing and associates resistance detection with phenotypic 
measurements. The PIT tracking-based AST is capable of label-free detection of antibiotic 
activity in real time and offers a quick, simple, and low cost comparison to the current 
clinical microbiology approaches. Moreover, this method offers single cell analysis 
capabilities that will be especially useful for quantifying susceptibility patterns of 
individual cells in polymicrobial clinical infections.  
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RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING OF UROPATHOGENIC E. COLI IN 
URINE SAMPLES BY TRACKING SUB-MICRON SCALE MOTION OF SINGLE 
BACTERIAL CELLS 
Antibiotic resistance infections are challenging to be treated at point-of-care due to the 
lack of a rapid antibiotic susceptibility testing (AST) technology to identify resistant 
infections at disease onset. Current clinical AST technologies take 1-3 days because of the 
slow culturing steps. Here, we demonstrate a rapid culture-free AST method by tracking 
sub-µm scale bacterial motion with bright field optical imaging. Clinically relevant 
bacterial pathogens E. coli O157:H7 and Uropathogenic E. coli (UPEC) are partially 
tethered to glass surface. Alive bacterial cells have on an average sub-µm motion above 
200 nm and dead bacterial cells killed by lethal dose of antibiotic polymyxin have a 
reduced motion below 100 nm. While the motion of dead bacteria is mainly from 
Brownian motion, we believe the larger sub-µm motion of alive bacteria is contributed 
from metabolism related activity. By analyzing dose dependent sub-µm motion changes 
of a population of bacterial cells in a multiplexed assay, we obtained minimum bactericidal 
concentration of polymyxin on the UPEC pathogens within 2 hours. We also applied the 
method directly to human urine samples spiked with bacteria and demonstrated rapid 
AST within 2 hours. The results are validated with the standard culture based AST method. 
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Introduction 
Antibiotic susceptibility testing (AST) is used clinically to diagnose antibiotic 
resistant strains and prescribe appropriate antibiotics.10,130 However, current AST 
technologies take 1-3 days due to their dependence on bacterial culturing.4,130 In the 
absence of rapid AST, physicians rely on community susceptible patterns and experience 
to often prescribe broad-spectrum antibiotics.3,33 This practice has contributed to the 
acceleration of bacterial resistance.3,29 A faster AST technique will empower physicians to 
prescribe effective narrow-spectrum antibiotics, preferably within 1-2 hour or shorter.4,92  
 Emerging AST technologies based on detecting bacterial growth rate via measuring 
cell numbers48,54,61, cell size46,91, and biochemical markers (RNA,50,67 DNA,68 or redox 
molecules51,75,76,131) have been developed (Chapter 2). Several culture-free AST 
technologies measuring bacterial metabolism such as bacterial nano-motion,26,44,122 heat-
signature,84,85 and biochemical profiles132 have also been pursued for real time AST 
(Chapter 2). While these technologies offer potential solutions, a simple and robust AST 
technology that can deliver accurate results within 2 hours requires further works. I 
introduces a rapid AST based on quantitating the sub-µm motion of bacterial cells 
captured with standard brightfield microscopy. 
The hydrodynamic133,134 and motility-induced long-range motions133,135 of live 
bacterial cells in the range of several µm near a surface have been studied using particle 
image velocimetry algorithms136 and digital holographic imaging technologies.134 However, 
short-range motion (a few nm) of surface-attached bacterial cells and their correlation to 
bacterial metabolism have only been recently studied using highly sensitive tools, such as 
atomic force microscopy44,77, and plasmonic imaging and tracking.23,26 In this work, by 
using simple brightfield imaging and automated image processing algorithms, we 
measured sub-µm motion of surface-tethered bacterial cells. We studied correlation of 
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sub-µm motion with bacterial viability and performed AST on clinically important strains, 
E. coli O157:H724 and Uropathogenic E. coli (UPEC), with antibiotic polymyxin.27 UPEC 
accounts for ~75% of all Urinary tract infections (UTIs), which affect over 10 million 
people,27 and often result in sepsis.27 Polymyxin is important because it is a last-line 
antibiotic for septic patients, and polymyxin-resistance strains have been found in UTI 
patients137,138,139  
To accomplish the goal of performing rapid AST within 2 hours on clinical urine 
samples, we performed multiple experiments. We first tethered bacterial cells onto the 
surface, and tested our algorithms to quantitate the sub-µm motion of tethered cells. Next, 
we measured the antibiotic induced sub-µm motion changes of individual cells with 
population-based statistical analysis. Then, we studied dose dependency of antibiotic 
induced motion changes in a multiplexed assay to determine the clinically relevant 
minimum bactericidal concentration of the antibiotic. Finally we demonstrated 2-hour 
AST on human-urine samples spiked with UPEC cells.   
Materials and Methods 
Materials 
Lyophilized pellets of bacteria E. coli O157:H7 (ATCC 43888) were purchased from 
Fisher Scientific and UPEC E. coli strain CFT073 was purchased from ATCC. Human urine 
samples, pooled from 20 healthy patients, was purchased from Bioreclamation IVT 
(WestBurry, New York) and stored at -80 °C. (3-Aminopropyl)triethoxysilane (APTES) 
was purchased from Sigma Aldrich, aliquoted to smaller volumes under vacuum and 
stored at 4°C in a desiccator. Affinity-purified goat anti-E. coli O157:H7 IgG polyclonal 
antibodies were purchased from Kirkegaard and Perry Laboratory Inc. (Gaithersburg, 
MD). Antibodies were further suspended in 1 ml PBS (1X), and stored in aliquots at -20°C. 
1-Mercapto-11-undecyl hexa(ethylene glycol) (PEG) and carboxyl-terminated 
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hexa(ethylene glycol) undecane thiol (PEG-COOH) were purchased from Nanoscience 
Instruments (Phoenix, AZ). Antibiotic Polymyxin B (PMB) was purchased from Sigma-
Aldrich, dissolved in 1x PBS at a stock concentration of 10 mg/ml and further stored in 
dark at 2-8°C according to manufacturer’s instruction. Other reagents were purchased 
from Sigma-Aldrich. 
Preparation and Growth of Bacteria  
The lyophilized E. coli O157:H7 bacteria were suspended in PBS, centrifuged at the 
speed of 50 x g for 1 min to pellet the charcoal. The supernatant containing bacteria was 
collected and centrifuged at 2000 x g for 15 min to pellet the bacteria. The bacterial pellet 
was re-suspended in 1 ml 1X PBS and mixed thoroughly. After 3 rounds of purification, 
the final 1 ml of bacteria in PBS solution was added with 5% glycerol, aliquoted into smaller 
volumes of 20 µl and stored at -80°C. Similarly, E. coli strain CFT073 strain was cultured 
on solid LB agar media, suspended in 1x PBS containing 5% glycerol and frozen in smaller 
aliquots at -80°C. 
An aliquot of frozen E. coli O157:H7 or E. coli CFT073 strain was thawed and used 
to inoculate 3 ml of LB medium one day prior to the experiments. Both strains were 
prepared before the experiment by diluting the overnight culture (grown at 37°C) into LB 
medium to a concentration of 107 colony forming units (CFU)/ml and continuing growth 
at 37°C with gentle rotary mixing until the cultures reached an OD600 of 0.56 which is the 
mid-logarithmic phase of growth. The corresponding concentration of the bacteria was 
4.67x108 CFU/ml. Bacterial cells were collected by centrifugation at 2000 x g for 15 min 
and re-suspended in 1 ml PBS (1X) to an OD of 0.56. For urine experiments, pooled urine 
samples were first filtered using a 0.2 um filter, followed by spiking urine with freshly 
cultured bacterial cells to a desired concentration. 
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Surface Functionalization 
Clean BK7 glass cover slips were coated with 1.5 nm chromium and 48 nm gold 
and used as PIT sensing chips. The chips were cleaned with deionized water, ethanol 
multiple times followed by drying with nitrogen gas and then cleaned by hydrogen flame. 
For antibody surface, the cleaned chips were submerged in 1 mM PEG/PEG-COOH 
ethanol solution and left in the dark for 24 h to coat a PEG/PEG-COOH self-assembled 
monolayer (SAM) on each chip. To attach antibodies next, the PEG/PEG-COOH SAM-
coated chips were activated with 500 μl of a freshly prepared mixture of 0.1 M NHS and 
0.4M EDC in 1:1 ratio to produce NHS ester receptors, which react with the primary amine 
groups on the antibodies via an amide bond. Chips with activated PEG/PEG-COOH SAM 
were cleaned with deionized water and blown dry with nitrogen gas. Polyclonal anti-E. 
Coli O157:H7 IgG antibodies dissolved in 20 mM sodium acetate (NaOAc), pH 5.5 at a 
concentration of 30 µg/ml were immediately applied to the NHS/EDC-activated surfaces 
and incubated for 30 mins. The antibody-coated chips were again cleaned with deionized 
water and dried with nitrogen gas prior bacterial cell capture on the imaging setups. 
For APTES surface, we used BK7 glass slides from VRW (Radnor, Pennsylvania) 
which were 22x60 mm. Further, the glass slides were thoroughly cleaned with deionized 
water and ethanol, followed by drying with nitrogen gas. To attach the APTES linker to the 
sensor surface, the glass slide was activated with freshly prepared 1% APTES in ethanol 
(with 5% water) for 15 seconds. The APTES linked sensor chips were again cleaned with 
ethanol, dried with nitrogen gas prior bacterial cell capture on the imaging setup. 
Imaging and Flow Setups 
The imaging setup consisted of an inverted microscope (Olympus IX-81) (Fig. 
1).103,104,110 A 60x oil immersion objective with numerical aperture (NA) of 1.49 or a 40x air 
objective (NA 0.75) was used to perform experiments. The APTES or antibody coated 
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slides were placed on the objective lens. Further, brightfield light was illuminated from 
top and a CCD camera (Pike-032B, Allied Vision Technologies, Newbuyport, MA, USA and 
GS3-U3-23S6M-C, PointGrey, Richmond, BC, Canada) was used to record images.  
For APTES coated glass slides, a black marker spot was placed beneath the coated 
surface, followed by placing a multi-well FlexiPerm (SARSTEDT) reusable well atop. The 
assembled glass coated chips was then mounted on top of the imaging setup. The 
brightfield light intensity was adjusted to an appropriate contrast without saturating the 
image. 
Bacterial Immobilization 
Bacterial cells of the strain E. coli O157:H7 (20 µl) were added to the sensor chip 
coated with antibodies, with a FlexiPerm well atop containing 500 µl PBS (1x). The cells 
tethered onto the sensor surface and after 10-15 min incubation at room temperature, 
sufficient bacterial cells were sufficiently attached to the surface. PBS buffer was 
subsequently flowed over the chip to remove unattached bacterial cells. Bacterial cells 
were elongated in length on the chip by culturing in Luria Broth media to validate that 
cells are metabolically alive and healthy, prior to performing experiments. 
UPEC cells in Urine or 1x PBS were added to the APTES coated surface with a 
Flexiperm multi-well atop.  Cells were incubated for 10-15 mins for cells to tether on the 
surface. If needed, 1-2 washes of 1x PBS using manual pipetting removed unattached 
bacterial cells. 
Image Collection and Processing 
All E. coli O157:H7 experiment image sequences were collected at 106 fps at a pixel 
resolution of 640x480 using pike camera. Images were recorded in either transmitted or 
plasmonic imaging mode for various time durations. All UPEC experiment image 
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sequences were collected at 26.6 fps at a pixel resolution of 1920x1200 using transmitted 
images via PointGrey camera. Further, we recorded images for 5s for each Well near the 
marker spot, followed by semi-automatically translating the stage to next marker spot 
below another well This was repeated every 15 mins for all wells across multiple time 
points. We chose an appropriate exposure time to maximize image intensity, avoid over 
exposure. The focus of the cell was appropriately chosen to image bright bacterial cells 
with darker backgrounds. All images from the videos were processed using custom-written 
MATLAB programs and ImageJ scripts.   
Sample Addition 
For, E.coli O157:H7, multiple sample solutions, such as LB medium, PBS  were 
added to the bacterial cells via a gravity-based multichannel drug perfusion system 
(Warner Instrument, Hamden, CT). The drug perfusion system flew sample solutions at a 
flow rate of 330 µl/min with the transition time between different solutions in the range 
of 1-2 sec. The flow system was stopped and stabilized for 5 min before recording videos. 
To deliver antibiotics for both E.coli O157:H7 and UPEC experiments, we pipetted small 
volumes of antibiotics into the Flexiperm well mounted on the microscope. 
Data Analyses from Images  
Image Segmentation and Cell Tracking Algorithm 
Greyscale images were converted into binary images using custom MATLAB 
scripts. For every greyscale image, we plotted a histogram of pixel intensities, which is 
unimodal.140 We computed a threshold value (T), at the point of drop in the intensity 
histogram towards the higher pixel intensity tail. All, pixel intensities higher than the 
threshold value T, where given a new intensity 1, while all the pixel intensities lower than 
the threshold were given a 0.  This gave us binary images with segmented cells from the 
background. Once segmented cells were obtained by the thresholding algorithm, standard 
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morphological operations such as removing spur points, breaking H-connected sections, 
filling holes were performed to improve segmentation.  The greyscale image of a bacterial 
cell is thus converted into a binary image with segmented bacterial cells from the 
background (Figure 5-1). Using regionprops MATLAB command, we further obtained a 
“Centroid” for each segmented cell (blue dot in Figure 5-1b) in the binary image. Centroid 
signifies the X and Y coordinates of the bacterial cell center and is calculated as the mean 
of all non-zero pixels which the bacterial cell occupies. We next tracked cell motion over a 
period of video. Each segmented cell in image In is matched to the previous frame In-1  if 
the centers are closest and within 1 cell length. This produces the motion of the center of 
the bacterial cell over a video. The X and Y displacement of the center (Figure S1c) was 
calculated by subtracting the X and Y coordinates of an individual cell from the cell’s mean 
position over the length of the video. 
The X and Y displacement of the center was calculated by subtracting the X and Y 
coordinates of an individual cell from the cell’s mean position over the length of the video. 
The “Distance” moved by the center of a bacterial cell was calculated by using the formula 
Distance = √𝜎𝑥2 + 𝜎𝑦2 where 𝜎𝑥  and 𝜎𝑦 represents the standard deviation of X and Y 
displacement respectively. Further, DAVG for a population of cells was calculated by taking 
the average of distances of individual cells. 
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Broth Micro-Dilution Assay 
Broth microdilution assay was used to determine the minimum inhibitory 
concentration from a previously described protocol.32 Frozen aliquots of CFT073 were 
thawed and cultured overnight. We prepared a bacterial suspension of 1 x 108 colony-
forming units (cfu)/ml of UPEC cells from overnight culturing. Further, antibiotic 
dilutions ranging from 0.125 µg/ml to 8 µg/ml were prepared in sterile Mueller Hinton 
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Figure  
5-1. Image Processing of Bacterial Cells to Quantitate X and Y Displacement.  
(a) Snapshot of a bacterial cell captured using our imaging setup as a greyscale image. 
(b) The greyscale image of a bacterial cell is converted into a binary image with the 
superimposed center of the cell (Blue dot in Figure 5-1b) (c) The center of the cell is 
plotted over 20s of video to obtain the displacement of every cell. Scale Bar – 1 µm 
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(MH) broth. 50 µl of antibiotic solutions were added to the 7 antibiotic wells, control well 
and sterility well in triplicate. Further, the bacterial suspension was diluted 1:100 before 
adding 50 µl to each of the wells above to a final concentration of 5 x 105 cfu/ml. The 96 
well plate was incubated at 37 oC for 16 hours. The optical density measurements of the 96 
well plate were measured using a spectrophotometer.  
Further, a 5 µl suspension after overnight culturing was spot plated on LB agar 
plates to measure the minimum bactericidal concentration of polymyxin for UPEC cells. 
We estimated MBC to be the concentration which failed to yield any positive bacterial 
cultures.  
Results and Discussion 
The experimental setup consisted of an inverted optical microscope attached with 
a CCD camera to record brightfield image sequences of bacterial cells (Figure 5-2). These 
images were analyzed using motion-tracking algorithms to perform rapid AST. Samples 
containing bacterial cells were added to a multi-well sample holder mounted on a glass 
side. The bacterial cells were tethered to the slide surface via antibody specific to bacterial 
surface antigens or a linker molecule, (3-Aminopropyl) triethoxysilane (APTES). The 
surface chemistry was optimized to make a large portion of the bacterial cells partially 
tethered to the surface, so that they still have sub-micron scale motions. Antibiotics at 
different concentrations were then added to different wells, and the bacterial cells tethered 
on the glass slide were imaged at different time points. The captured image sequences 
were processed to determine changes in the bacterial motion before and after the addition 
of antibiotic. Clinically relevant minimum bactericidal concentration (MBC) was 
determined by analyzing the motion of a population bacteria cells exposed to different 
antibiotic doses.  
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Figure  
5-2. Schematic of the Experimental Setup to Image and Track Bacterial Cell Sub-m 
Motions  
Step 1 – Live bacteria spiked human urine samples are added to a multi-well glass slide 
allowing bacterial cells to tether onto the glass surface. Step2 – Individual wells of the 
slide are imaged by the microscope, and the motions of tethered bacterial cells are 
quantitated via image analysis. Step3 – Different doses of antibiotics are added to the 
wells on the slides, and the changes in bacterial cell motions are recorded. Step 4 – 
Image analysis reveals that the bacterial cells show a decrease in motion after expose 
to antibiotics (blue bar – motion before antibiotic, red bar – motion after antibiotic). 
Statistical analysis on a population of cells for each antibiotic dose is performed, and 
an antibiotic dose curve is obtained. 
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Quantification of the Bacterial Motion 
Alive E. coli O157:H7 bacterial cells were tethered to the glass slide by an antibody 
specific to the cell-surface glycan antigen and imaged by an optical setup (Figure 5-2a).20 
The centroid (center) of each bacterial cell was extracted in each image frame using the 
procedure described in the materials section (Figure 5-1). Blue dots superimposed over 
the bacterial cell in Figure 5-3a are the center positions of the cell at different moments 
over a 20-second period. The displacements of the bacterial cell are more clearly shown in 
the zoomed-in plot in Figure 5-3b, revealing sub-µm scale motion of the cell tethered to 
the surface. For quantitative analysis of the sub-µm motion of the bacterial cell, we defined 
“Distance” derived as the root-mean-square of the displacement, over 20s. The distance 
for different bacterial cells varies from 75 nm to 842 nm (Figure 5-3c), with an average of 
265 nm. The error in extracting the center positions of the bacterial cells was determined 
to be 25 nm, by calculating the distance of a fixed marker spot (pillars attached within a 
microfluidic cassette)141 (Figure 5-4). This error was much smaller than the average 
distance (278 nm) of the typical bacterial cell shown in Figure 5-3a. This result validates 
the ability of our method to quantitate the sub-µm motion of the bacteria cell. A population 
of bacterial cells tethered to the surface has both partially bound and tightly bound cells 
(e.g Cell 4,8 and 9 in Figure 5-3c). The tightly bound alive cells have been previously 
exhibited to show z-direction motion using plasmonic imaging.26  
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Figure  
5-3. Bacterial Cells Tethered on a Surface with Sub-µm Motion 
(a) A snapshot of a bacterial cell with superimposed motion of the cell center over 20s 
shown via blue dots. (b) Displacement of the cell center over 20s, reflecting the sub-µm 
motion of the cell (c) Distance, defined as the root-mean-square of the displacement of 
cell center over 20s, of 9 different bacterial cells. Scale Bar – 1 µm. 
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Figure  
5-4. X and Y Displacement of a Bacterial Cell Compared to a Fixed Spot  
(a1) Snapshot of a bacterial cell captured using our imaging setup with superimposed 
displacement of the center shown via blue dots (a2) Enlarged displacement of the center 
of the cell over 20s. (b1) Snapshot of a fixed marker captured using our imaging setup with 
superimposed displacement of center shown via blue dots (b2) Enlarged displacement of 
the center of the marker over 20s shown. The error of our imaging algorithm was found to 
be 25nm. Scale Bar – 1 µm 
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Effect of Antibiotic on the Sub-µm Motion 
To correlate bacterial metabolism and sub-µm motion exhibited by surface tethered 
bacterial cells, we added the antibiotic polymyxin. After imaging bacterial cells in 1x PBS, 
polymyxin at a bactericidal concentration of 0.5 mg/ml was added, and the concurrent 
change in the bacterial motion was monitored (Figure 5-5). Figures 5-5a1 – 5-5a3 show 
the brightfield images of the alive bacterial cell partially tethered to the surface, where blue 
and red dots are the sub-µm motion of the bacteria before adding the antibiotic, 2 mins 
and 5 mins after adding the antibiotic. Zooming-in of the displacements reveals more 
clearly the sub-µm motion and decrease in motion associated with the addition of 
antibiotics (Figure 5-5b1-5-5b3). For a bacterial cell before adding the antibiotic, the 
distance over 20s is 278 nm (Figure 5-5c - blue bar). 2 mins after adding the antibiotic, 
the motion of bacterial cell decreases as observed in the scatter plot (Figure 5-5b2) with a 
decreased distance of 225 nm (Figure 5-5c – red bar). This decrease in sub-µm motion is 
due to the action of antibiotic. 5 mins after adding the antibiotic, the distance of the 
bacterial cell reduces to 65 nm (Figure 5-5b3 and Figure 5-5c) along with a visible decrease 
in bacterial cell size. The decrease in cell size is due to cell lysis, which is known attribute 
of bactericidal action of antibiotics.13 The metabolically dead state of the cells post the 
addition of antibiotics was also validated by overnight culturing, which failed to yield any 
alive cells.  Thus, the sub-µm motion exhibited by single bacterial cells is a signature of a 
bacterial cell’s metabolism state. Further, adding antibiotics led to a decrease in the 
motion, which can be quantified to perform antibiotic susceptibility analysis of antibiotics 
to individual cells.  
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Figure  
5-5. Sub-µm Motion Before and After Adding Antibiotic for Single Cells as Well as a 
Population 
Snapshots of cells before the antibiotic in 1xPBS and after adding the antibiotic 
polymyxin B at a bactericidal concentration of 0.5 mg/ml. (a) Snapshots of a bacterial 
cell with superimposed displacement of center of cells at different time points in 1x PBS 
and after adding the antibiotic. (b) Displacement of the center of the bacterial cell over 
20s at various time points c) Distance of the cell at various time points d) DAVG of a 
population of cells before and10 mins after the addition of 0.5 mg/ml of the antibiotic 
polymyxin.  Scale bar – 1µm. 
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Population Level Bacteria Motion Changes on Antibiotic Action 
While partially tethered cells showed a decrease in the sub-µm motion upon exposure to 
the antibiotic, tightly bound cells didn’t show any changes. To successfully use brightfield 
imaging for AST, it’s important to obtain measurable changes in the sub-µm motion on 
antibiotic action for a population of bacterial cells on a chip, containing a mixture of 
partially and tightly bound cells. We studied the effect of antibiotic on “Average Distance”, 
denoted by DAVG for a sample of bacterial cells. DAVG is measured by averaging distances of 
individual cells, including tightly bound and partially bound cells. The DAVG due to sub-µm 
motion for a sample of cells before adding the antibiotic is 265 nm (Figure 5-5b) which 
reduces to 123 nm within 10 mins after adding bactericidal concentration of antibiotic 
polymyxin. This indicates that we can carry susceptibility testing based on calculating sub-
µm motion holistically to a population of cells on a given chip, without filtering for only 
the partially tethered cells. 
Application to UPEC with Multiple Antibiotic Doses 
We next tested the applicability of our approach to the clinically relevant UPEC strain. 
UPEC cells were tethered to glass surface with a more general linker using APTES surface 
chemistry, which conjugates to the amine group of the bacterial surface protein. Also, the 
antibiotic dose dependent experiments were performed in a multiplexed format using a 
multi-well slides and a 40x air objective so that rapid imaging amongst the wells is feasible. 
We incubated bacterial cells in 5 different wells (Well 1 to Well5), and recorded an initial 
baseline image sequences at 0 min for each of the wells. Further, we added a clinical 
relevant dosage of antibiotic in increasing concentrations from 0 to 4 µg/ml across 
different wells and recorded image sequences at 15 min interval for all wells. After 75 mins, 
we added 0.5mg/ml antibiotic polymxin (positive control dose that is supposed to kill all 
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bacteria) across all wells and recorded again after 15 mins (at 90 min) of lethal dose 
addition. 
Control Well 
Well1, which has no antibiotic for the first 75 mins, has an initial DAVG of 228nm (Figure 
5-6a) with 100 cells (Figure 5-7a) tethered to the surface initially. Over time, the number 
on cells on the surface gradually increases (Figure 5-7a) on account of active replication of 
surface tethered cells (Figure 5-8 and Figure 5-9). The DAVG of the population increases 
from 228nm to 388nm from 0 min to 15 mins, followed by a gradual decrease from 388 
nm to 227 nm over 75 mins (Figure 5-6a). The decrease in DAVG can be due to depleted 
nutrients per cell over time. On adding the positive control dose of antibiotic after 75 mins, 
we observed (Figure 5-6a) a huge decrease in the DAVG of cells from 227 nm to 64 nm. This 
result validated that the sub-µm motion of surface tethered UPEC cells with APTES 
chemistry is correlated with its metabolism and can be used to perform susceptibility 
testing. 
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Figure  
5-6. D
AVG
 of a population of cells in different wells at various time points.  
Wells are sequentially exposed to 1xPBS (blue bar, the base line measurement), 
different clinically relevant doses of antibiotics (red bars, antibiotics added 
immediately after the baseline measurement), and a lethal dose of antibiotic (brown 
bar, 0.5 mg/ml added after the 75 min measurement) a)-e) D
AVG
 of cells in Well1-Well5 
with 0 µg/ml – 4 µg/ml of antibiotic respectively. f) Antibiotic dose curve of normalized 
D
AVG 
at 75 mins. 
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Figure  
5-7. Number of UPEC Cells in Different Wells over Time. 
Total number of bacterial cells in different wells at different time points, where they are 
sequentially exposed to 1xPBS (blue bar, the base line measurement), different 
clinically relevant doses of antibiotics (red bars, antibiotics added immediately after the 
baseline measurement), and a lethal dose of antibiotic (brown bar, 0.5 mg/ml added 
after the 75 min measurement) a)-e) Total cells in Well1-Well5 with 0 µg/ml – 4 µg/ml 
of antibiotic respectively. 
  
 
 
 
Figure  
5-8. Changes in Sub-µm Motion of a UPEC Cell Replicating on the Surface.  
a1-a4 Snapshots of a UPEC cell with superimposed displacement of the center over time in 1x PBS followed by addition of 
0.5mg/ml antibiotic. b1-b4 Scatter plot of displacement over time in 1xPBS followed by adding 0.5mg/ml antibiotic. c) Bar 
graph showing changes in distance  
a4 
b2 b3 b4 
T=0 min  
1x PBS 
T=30 min 
1x PBS 
T=60 min 
1x PBS 
a1 a2 a3 
b1 
T=15 min 
0.5 mg/ml Polymyxin 
c 
b 
a 
-600 -400 -200 0 200 400 600
-600
-400
-200
0
200
400
600
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
-600 -400 -200 0 200 400 600
-600
-400
-200
0
200
400
600
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
-600 -400 -200 0 200 400 600
-600
-400
-200
0
200
400
600
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
-600 -400 -200 0 200 400 600
-600
-400
-200
0
200
400
600
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
0 30 60 90
0
200
400
600
800
1000
0.5 mg/ml 
Polymyxin
1x
PBS
 Time (min) 
D
is
ta
n
ce
 (
n
m
)
90 
  
 
 
 
Figure  
5-9. Changes in Sub-µm Motion of a UPEC Cell Replicating on the Surface  
a1-a4 Snapshots of a UPEC bacterial cell with superimposed displacement in 1x PBS followed by addition of 0.5mg/ml 
antibiotic. b1-b4 Scatter plot of displacement over time in 1xPBS followed by 0.5mg/ml antibiotic. c) Bar graph showing 
increase in distance  
T=0 min 
1x PBS 
T=30 min 
1x PBS 
T=60 min 
1x PBS 
T=15 min 
0.5 mg/ml Polymyxin 
a4 
b2 b3 b4 
a1 a2 a3 
b1 
c 
b 
a 
-1500 -1000 -500 0 500 1000 1500
-1500
-1000
-500
0
500
1000
1500
X- Displacement (nm)
Y
- 
D
is
p
la
c
e
m
e
n
t 
(n
m
)
-1500 -1000 -500 0 500 1000 1500
-1500
-1000
-500
0
500
1000
1500
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
-1500 -1000 -500 0 500 1000 1500
-1500
-1000
-500
0
500
1000
1500
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
-1500 -1000 -500 0 500 1000 1500
-1500
-1000
-500
0
500
1000
1500
X- Displacement (nm)
Y
- 
D
is
p
la
ce
m
en
t 
(n
m
)
0 30 60 15
0
500
1000
1500
0.5 mg/ml 
Polymyxin
1x 
PBS
 Time (min) 
D
is
ta
n
ce
 (
n
m
)
91 
  
 
 
 
2
1     
1    
2    
1    
2   
1   
2   
T=0 min 
1x PBS 
T=30 min 
0.25 µg/ml  
Polymyxin 
T=60 min 
0.25 µg/ml  
Polymyxin 
T=15 min 
0.5 mg/ml  
Polymyxin 
a4 a1 a2 a3 a 
b c Bacteria1 Bacteria2 
0 30 60 15
0
1000
2000
3000
4000
5000
0.5 mg/ml 
Polymyxin
1x PBS 0.25 g/ml 
Polymyxin
 Time (min) 
D
is
ta
n
ce
 (
n
m
)
0 30 60 15
0
500
1000
1500 0.5 mg/ml 
Polymyxin
1x PBS 0.25 g/ml 
Polymyxin     
 Time (min) 
D
is
ta
n
ce
 (
n
m
)
Figure  
5-10. Decrease in Sub-µm Motion of a UPEC Cell on the Surface in 0.25 µg/ml of Antibiotic  
a1-a4 Snapshots of two individual UPEC bacterial cell with superimposed displacement in 1x PBS followed by addition of 
0.25 µg/ml antibiotic. b) - c) Show distance at different time points. Both the cells show a decrease in distance at 30mins and 
60mins on adding a low dosage of 0.25µg/ml of antibiotic (red bars). These cells are representative of sub-population1 on 
which low dosage of antibiotic acts immediately and which dominates the initial decrease in DAVG of the population.  
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Figure  
5-11. Increase in Sub-µm Motion of a UPEC cell on the Surface in a 0.25 µg/ml of Antibiotic  
a1-a4 Snapshots of an individual UPEC bacterial cell with superimposed motion over time in 1x PBS followed by addition of 0.25 
µg/ml antibiotic. b) Bar graphs of motion at different time points. The cells show an increase in distance at 30mins and 60mins, 
on adding a low dosage of antibiotic as evident in bar graph (red bars). These cells are representative of sub-population2 on 
which low dosage of antibiotic doesn’t act and which dominates the later increase in DAVG of the population.  
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Figure  
5-12. Decrease in Sub-µm Motion of a UPEC Cell on the Surface in a 2 µg/ml of Antibiotic  
a1-a4 Snapshots of an individual UPEC bacterial cell with superimposed motion over time in 1x PBS followed by addition of 2 µg/ml 
antibiotic and 0.5 mg/ml antibiotic. b) Bar graphs of motion at different time points. The cells show a decrease in motion at 30mins 
and 60mins, on adding a low dosage of antibiotic (red bars). The decreased motion is equal to the decrease observed after adding 
the bactericidal concentration of 0.5 mg/ml, indicating cell-death on adding 2 µg/ml antibiotic. 
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Figure  
5-13. Decrease in Sub-µm Motion of a UPEC Cell on the Surface in a 2 µg/ml of Antibiotic  
a1-a4 Snapshots of an individual UPEC bacterial cell with superimposed motion over time in 1x PBS followed by addition of 
2 µg/ml antibiotic and 0.5 mg/ml antibiotic. b) Bar graphs of motion at different time points. The cells show a decrease in 
distance at 30mins and 60mins, on adding a low dosage of antibiotic (red bars). There is a further decrease observed after 
adding the bactericidal concentration of 0.5 mg/ml, indicating that this individual cell might not be dead on adding 2 µg/ml. 
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Bacteria Motion Responses to Clinically Relevant Antibiotic Doses 
For wells 2-5 with different antibiotic dosages, we observe immediate decreases in 
the DAVG (Figure 5-6b to 5-6e) of the cell-population at 15 mins compared to initial values 
at 0 min in each well.  Over 75 mins, all antibiotic wells except Well2 (explained later) 
showed a gradual decrease in DAVG, indicating decrease in sub-µm motion over time. The 
number of cells across in wells with 0.5-4 µg/ml antibiotic doses remains steady over 75 
mins (Figure 5-7), indicating cessation of bacterial replication in the presence of 
antibiotics. After adding the lethal dose across all wells at 75 mins, we observed a further 
decrease in DAVG of the cell-population in all antibiotic wells except Well5, in which the 
DAVG remains similar. Different decreases in DAVG in various wells, signifies that the sub-
µm motion changes are scaled with the concentration of the antibiotics, providing a strong 
evidence that this method can be used to measure dose dependence antibiotic action.  
Single Cells Analysis and Cell to Cell Variations in Motion Responses to 
Antibiotics    
Observing single cells in different wells gives us interesting insights into the sub-
µm behavior of cells at low dosages of antibiotic. In Well1, individual cell (Figures 5-8 and 
5-9) at different time points show clearly that the distance of actively replicating cells 
generally increases as cells replicate followed by a decrease on adding antibiotics. This 
further validates that sub-µm motion is correlated with bacterial metabolism. However 
establishing a more precise relationship between bacterial metabolism and the sub-µm 
motion of surface tethered cells will need additional research going forward. In Well2, for 
the entire sample of cells, there is a steady decrease in DAVG from 0 min to 60 mins followed 
by an increase at 75 mins, which is due to two distinct subpopulations (sub-population 1 
and sub-population 2) of cells. In sub-population1 (Figure 5-10), there is an immediate 
decrease in distance of individual cells on adding a low dose antibiotic, whereas in sub-
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population 2, there is an increases in distance as the bacterial cells continue to divide in 
the presence of low dosage of antibiotic (Figure 5-11). Towards 75 mins sub-population2 
dominates leading to an overall increase in DAVG for the complete well. Both sub-
populations show a decrease in distance on adding the lethal antibiotic dose after 75 mins. 
These results means that sub-population 2 is more resistive to the antibiotic than sub-
population 1, indicating the heterogeneous responses to antibiotic treatment among the 
bacteria population, and the power of single cell sub-µm motion analysis for finding sub-
population of resistant strains in a sample. In Well4, all individual cells (Figure 5-12 and 
5-13), decrease their distance immediately post the addition of 2 µg/ml antibiotics. 
However, for some cells (Figure 5-12) the distance doesn't recover over time and is 
comparable to the distance obtained after subsequent addition of the lethal dose. This 
result means that the particular cells is killed at 2 µg/ml of antibiotic.  
Dose-curve and Defining MBC for Sub-µm Motion 
To obtain the antibiotic dose dependent changes on the motions, we normalized 
the DAVG at 75 min from each well, to the DAVG values between a particular Well’s control 
measurement at 0 min and positive control measurement at the lethal 0.5mg/ml antibiotic 
dose. Figure 5-6 is the dose curve obtained at 75 mins, which shows a steady decrease in 
the normalized DAVG as the antibiotic dosage is increased. At 4 µg/ml antibiotic 
concentration (Figure 5-6f), the normalized DAVG value (0.08) is close to 0, indicating 4 
µg/ml to be the minimum bactericidal concentration, defined for our particular assay as 
the minimum antibiotic concentration where the DAVG is close to the average motion 
distance at a known bactericidal concentration. We further compared our MBC value to 
the gold standard culture based method, which gives a MIC value of 1 µg/ml (Figure 5-14) 
and MBC value of 2 µg/ml (data not shown). Our MBC value obtained within 2 hours is 
close to the reference techniques which require 24-72 hours to obtain the MIC and MBC 
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values. Our MBC is within the QC range of Clinical & Laboratory Standards Institute 
(CLSI), indicating our technology can provide clinically significant MBC values and 
perform rapid AST within 2 hours. 
 
 
 
 
 
 
Urine Samples 
To test the feasibility of our method to work directly on clinical samples, we spiked UPEC 
bacterial cells in urine samples collected from healthy patients. Following surface 
tethering, we recorded image sequences from 6 different wells with antibiotic doses 
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Figure  
5-14. Comparison with Reference Techniques  
Using optical density measurement, we measured the minimum inhibitory 
concentration (MIC) of polymyxin against UPEC strain is 1µg/ml. The Minimum 
Bactericidal Concentration (MBC) was obtained by spot plating individual 
concentrations. The MBC is found to be 2µg/ml 
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between 0 µg/ml to 8 µg/ml. From 0 µg/ml to 2 µg/ml, the DAVG is steady or increases over 
time (Figure 5-15a to 5-15c). The increase in sub-µm motion between 0 min and 90 mins 
in Well1 to Well4 should be due to sufficient nutrients in urine that promote bacterial cells 
divide. This is in contrast to measurements in 1x PBS, where the bacteria sub-µm motion 
decreases over time due to depleted nutrients. After adding the lethal dose, Well1 to Well4 
show a sharp drop in DAVG within 15 minutes (Figure 5-15a-5d). Well 5 and Well 6 (4 µg/ml 
and 8 µg/ml) show immediate drop in DAVG (Figure 5-15e and 5-15f), and negligible drops 
in DAVG upon adding the lethal dose (Figure 5-15e and 5-15f). In well 6, with 8 µg/ml 
antibiotic, the DAVG at 90 minutes is indifferent from the positive control at a lethal dosage. 
We estimate 8 µg/ml to be the MBC of polymyxin against UPEC strain in Urine samples.  
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Figure  
5-15.  D
AVG
 of a Population of Bacterial Cells Spiked in Urine to a Concentration of 
5x10
6
 cfu/ml. 
Different wells at different time points are sequentially in Urine (blue bar, the base line 
measurement), different clinically relevant doses of antibiotics (red bars, antibiotics 
added immediately after the baseline measurement), and a lethal dose of antibiotic 
(brown bar, 0.5 mg/ml added after the 90 min measurement) a)-e) D
AVG
 of cells in 
Well1-Well6 with 0 µg/ml – 8 µg/ml of antibiotic respectively.  
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On repeating this experiment for different concentrations of spiked bacterial cells in urine 
samples, we predict a range of MBC between 4-8 µg/ml for polymyxin B using our method. 
This number is in close agreement with previous experiments and gold standard 
techniques which take 24-48 hours to obtain the clinical MBC. This validates the ability of 
our technique to perform rapid AST within 2 hours, directly on urine samples.  
Table 
5-1. MBC of the Antibiotic at Different Concentrations of UPEC cells Spiked into 
Urine 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteria Concentration in Urine Estimated MBC 
5x10
6
 cfu/ml 8 µg/ml 
10
7
 cfu/ml 4 µg/ml 
10
8
 cfu/ml 4 µg/ml 
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Conclusion  
The motility-induced motion of bacterial cells close to the surface or swimming in 
the solution has been previously studied using multiple optical techniques.134,142 Bacterial 
cells have also been studied by attaching them firmly to the surface to enable imaging 
within the field of focus.13 However, none of the previous approaches quantify the sub-µm 
motion of surface tethered bacterial cells and apply it for AST. Our approach has been 
made possible by optimizing the surface chemistry which enables capture of sufficient 
number of partially tethered cells close to the surface. For the antibody surface chemistry, 
we optimized the time of incubation of antibody on the surface while for APTES surface 
chemistry, we optimized both the time of incubation and APTES concentration. As we have 
shown these partially tethered cells show a decrease in the sub-µm motion on antibiotic 
action, while strongly tethered cells don’t show any visible changes in sub-µm motion 
using brightfield imaging. To quantify the motion changes of free cells in solution post 
antibiotic action is challenging, because of the Brownian-motion of these cells, which 
superimposes on the metabolic motion of such cells.  
We demonstrated rapid (within 2 hours) AST of clinically important strains, E. coli 
O157:H724 and UPEC, by quantifying the sub-µm motion of single bacterial cells with 
optical tracking. Compared to culture based methods that measure increases in cell size or 
numbers, our approach is faster. Compared to AFM, which measure bacterial nano-
motion in z-direction, our present bright-field based optical tracking method can 
simultaneously imaging multiple bacterial cells in parallel and provide single-cell 
resolution that can be used for poly-microbial analysis as well as finding resistant sub-
populations. Compared to plasmonic imaging and tracking (PIT) reported by us in a 
previously publication, the present optical tracking is simpler in both instrumentation and 
sensor chip preparation. One limitation of the present method compare to PIT is the lack 
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of resolution in Z direction. However, out results shows that tracking of x/y sub-µm 
motion is sufficient for the purpose of AST. While we were able to obtain clinically relevant 
MBC values within 2 hours in urine samples, possible limitations of our method include 
the inability to perform this analysis at lower concentrations of bacteria in Urine. However, 
this limitation can be potentially overcome by pre-concentrating bacterial cells from 
patient samples with filtration/centrifuge or microfluidic captures, and by improving 
surface chemistry to enable uniform partial tethering across all cells. While we showed a 
direct correlation between the sub-um motion and bacterial viability, the applicability of 
our technique to a wider set of bacteriostatic antibiotics needs further study. However, 
since previous studies have shown the applicability of using nano-motion to other 
antibiotics such as ampicillin, streptomycin and other bacterial strains,26,44,122, we have 
confidence that our method will work for other cases as well. 
We have demonstrated a rapid AST using sub-µm bacterial motion with a 
turnaround time of 2 hours and capable of working directly with urine samples. The sub-
µm bacterial motion is a signature of its metabolism and is also dependent upon the degree 
of a cell’s surface attachment. The sub-µm motion decreases on antibiotic action for 
partially tethered cells, while no such changes happen in tightly tethered cells. Despite 
variability amongst cells, we can use sub-µm motion to perform susceptibility testing for 
a population of cells. By analyzing dose dependent sub-µm motion changes in a 
multiplexed assay, we obtained within 2 hours minimum bactericidal concentration of 
polymyxin against UPEC. We plan to conduct more research to validate our method for a 
broader set of antibiotics, pathogens and clinical conditions. We anticipate that clinical 
labs with brightfield imaging would be able to incorporate our methodology in parallel to 
already existing microscopic urinalysis protocols. This will greatly ease the adaptation 
challenges which other AST tools might face. Further, with the advent of paper 
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microfluidics,143,144 low-cost microscopy such as Foldoscope145 and smart-phone based 
diagnostics,146,147 we anticipate our tool to be coupled with such techniques to perform 
point-of-care rapid AST, to reach a much broader audience in the developing world, which 
face a humanitarian crisis of resistant bugs.  
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                                   CONCLUSION AND FUTURE WORK 
Conclusions 
I developed a culture-independent AST, based on quantifying the motion of 
surface-tethered bacterial cells using two separate imaging techniques. I also developed 
plasmonic imaging technique to quantify cell-to-cell heterogeneity with potential 
applications in antibiotic drug development. In Chapter 3, I measured kinetic constants of 
antibody interactions with single cells and found out that these interactions are “noisy” 
due to small-micromotion of alive bacterial cells. The distribution of kinetic constants is 
unimodal and spread over four orders of magnitude which reflects cell-to-cell 
heterogeneity in bacterial surfaces present within a population. The center of the unimodal 
distribution, is similar to the value found in the literature by techniques measuring 
interactions of antibody with bulk populations. This validated the use of the plasmonic 
technique to quantify bacterial heterogeneity and gain more information about 
evolutionary microbial diversity while developing new antimicrobials and humanized 
antibodies as future therapeutic drugs against bacterial surfaces. 
In Chapter 4, I correlated small-micromotion present in surface tethered cells to 
z-direction vibration of alive bacterial cells. Using PIT, we tracked z-direction motion with 
sub-nm precision and found out that alive bacterial cells vibrate in the z-direction with 
nano-meter scale amplitude (nano-motion) of 5-10 nm. We discovered nano-motion as an 
effective signature of bacterial metabolism, which changes in different nutrient and 
culture conditions. Nano-motion increases in the presence of active metabolic substances 
such as glucose and decreases on giving antibiotics, which we used to perform antibiotic 
susceptibility testing. We showed that the principle of AST based on quantifying nano-
motion can be universally applied to multiple strains (UPEC, E. coli O157), multiple 
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antibiotics (polymyxin, streptomycin) and different surface tethering molecules 
(antibodies, APTES). 
In Chapter 5, I enabled simple brightfield microscopes, present commonly in 
clinical labs across the healthcare world, to perform rapid AST within 2 hours on UPEC 
strains directly in urine samples. I demonstrated that via an optimal combination of 
surface chemistry, hardware changes and automated image processing algorithms, we can 
perform susceptibility testing by quantitating the sub-um motion of bacterial cells. 
Partially tethered bacterial cells show sub-um motion with an average of 260nm, tightly 
tethered bacterial cells show decreased sub-um motion of about 75nm. The sub-um 
motion decreases on antibiotic action of partially tethered cells and no such changes 
happen in tightly tethered cells. For a population of cells, containing a mixture of cells with 
different degrees of surface attachment, we observe a decrease in average motion (DAVG) 
on antibiotic action at a lethal dose. We performed multi-dose experiments in a multi-well 
format at clinically relevant concentrations and estimated minimum bactericidal 
concentration (MBC) of polymyxin against UPEC strains within 2 hours. We also 
estimated MBC directly in urine samples spiked with different bacterial concentrations. 
Our MBC estimate was in good agreement with current gold standard culturing techniques 
which take 3 days, thus enabling point-of-care use. 
Future Work  
To achieve long term impact both in the pharmaceutical and clinical microbiology, I 
discuss future projects which can be built on the current work. 
1. Study AST application of 3D motion of surface tethered UPEC bacteria for 
different classes of antibiotics. To investigate broad applicability of our method 
and for a faster clinical adaptation, it is important to quantify 3D movement of 
UPEC in the presence of different classes of antibiotics: ampicillin (ß-lactam), 
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kanamycin (aminoglycoside), tetracycline, ciprofloxacin (quinolone). We 
anticipate that the antibiotics, which affect cell wall synthesis, protein 
synthesis, or DNA replication, will have an effect on active cellular motion. 
Monitoring 3D cellular movement and comparing inhibitory and killing effects 
of bacteriostatic and bactericidal antibiotics, respectively, will help establish a 
rapid AST. Action of antibiotics can be orthogonally validated using previously 
well characterized strategies such as engineering E. coli with protein 
fluorescent tags, culturing in media to check for cell growth. While it’s possible 
that motion changes due to bactericidal antibiotics within 2 hours are minimal, 
we expect a dose dependent response which should be helpful to estimate 
MIC/MBC. 
2. Correlate cellular metabolism and motility with 3D cellular movement. To 
investigate the metabolic causes behind 3D motion of surface tethered bacteria, 
it’s important to perform this study. Measuring the 3D movement of UPEC in 
various culture media, with and without supplements and metabolites (i.e., 
tryptophan, cas-amino acids, maltose, glucose, different carbon sources), and 
at various temperatures will change cellular growth and metabolism along with 
giving a better understanding of underlying phenomenon. To differentiate 
cellular metabolism and motility effects on the cellular movement, we can also 
study UPEC E. coli CFT073 (Gram negative, rod-shaped, motile) and E. coli 
CFT073 ΔfliC mutant (non-motile mutant without flagella). These experiments 
will allow us to differentiate metabolism and motility-related 3D movements 
and correlate the movements of viable bacteria to physiological processes. 
Another strategy is to monitor the effect of stimuli on motility in normal and 
abnormal cells. For example, after the addition of L-serine (attractant) to 
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induce continuous running and block tumbling or sodium benzoate (repellent) 
to induce continuous tumbling, UPEC chemotactic responses can be monitored 
by light microscopy and then assessed for 3D movement. This study will 
examine the potential interdependence of 3D movement and E. coli flagella 
and changes in 3D movement with differentially induced motility phenotypes. 
Further, this aim will also help understand the applicability of this principle to 
UPEC strains with repressed motility. 
3. Studying bacterial strains directly in clinical urine samples to enable rapid, 
point-of-care AST for application in clinical samples. It’s important to test the 
feasibility of this approach for a wider range of real-patient conditions. Urine 
samples must be tested containing UPEC pathogens from diverse patients 
accounting for diversity in gender, age, past-surgical procedures, catheter 
related UTIs, past resistant history. This study will be useful in developing a 
protocol to enrich bacterial cells from urine, separation of eukaryotic material 
from bacterial cells, testing upper and lower limits of detection for different 
bacterial concentrations in clinical samples as well as establishing healthy 
nutrient conditions to enable sub-µm motion for AST testing. This will 
eventually be useful in carrying out a multi-center comparative study closer to 
regulatory approval.  
4. Studying combined kinetic interactions and nano-motion changes of antibiotic 
action on bacterial cells. In the pharmaceutical industry, kinetics of antibiotic 
interaction with bacterial surface and MIC testing of an antibiotic against a 
bacterial cell is carried out in two separate diverse assays. However, both these 
phenomenon are fundamentally similar in nature and can lead into interesting 
insights into resistant mechanisms. We propose a single step assay, using PIT, 
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capable of studying kinetic interactions and nano-motion changes together for 
single bacterial cells. We hypothesize that resistant and susceptible strains, 
which have resistant markers on the surface, will have different kinetic 
interactions with antibiotics. This will help elucidate binding potential of new 
antibiotics and quantitate bacterial heterogeneity. We also expect differential 
changes in 3D motion varying with antibiotic dosage which can give insights 
into single cell behavior. Potential pitfalls might be that antibiotics are small 
molecules and they might not lead to measurable kinetics. Also, at low dosage 
of antibiotics, the longer time scales might not be amenable to perform kinetic 
studies.  
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